[
{
"nct": "NCT00005947",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Sipuleucel-T, autologous cellular immunotherapy for prostate cancer."
},
{
"nct": "NCT00065442",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Sipuleucel-T, autologous cellular immunotherapy for prostate cancer."
},
{
"nct": "NCT00090220",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"hpv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Took the base-study groups (Day 1 to about Month 48); left out EG002 (open-label qHPV in EXT1) and EG003 (long-term follow-up of vaccinated participants)."
},
{
"nct": "NCT00090233",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"rotavirus"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "RotaTeq (live human-bovine reassortant) vs placebo matching RotaTeq; placebo composition not given. SAE and other-AE tables use the same two groups."
},
{
"nct": "NCT00090285",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"hpv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Took the base-study groups; left out EG002 (open-label qHPV in EXT1) and EG003 (LTFU, mixes both base-study arms)."
},
{
"nct": "NCT00092443",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"rotavirus"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Placebo described only as matching RotaTeq."
},
{
"nct": "NCT00092456",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"rotavirus"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Pooled three RotaTeq lots; placebo described only as matching RotaTeq."
},
{
"nct": "NCT00092521",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"hpv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Quadrivalent HPV (EG000) and monovalent HPV 16 vaccine (EG001) against one placebo, base study; left out EG003 (extension, open-label qHPV for those not fully vaccinated, mixes arms)."
},
{
"nct": "NCT00092534",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"hpv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Took Base Study groups 1 (qHPV, Gardasil, aluminium adjuvant) and 2 (placebo). Left out EG002 (Base Study EXT, placebo recipients crossed over to qHPV) and EG003/EG004 (LTFU, after crossover). 'Matching placebo' composition not stated in the record."
},
{
"nct": "NCT00092547",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"hpv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Took the base-study groups (Day 1 to Month 30); left out EG002 and EG003 (extension Month 30 onward, placebo recipients then given qHPV)."
},
{
"nct": "NCT00094653",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "gp100 melanoma peptide vaccine with or without ipilimumab."
},
{
"nct": "NCT00095576",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"hiv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "MRKAd5 HIV-1 gag/pol/nef (Ad5 vector) preventive vaccine in HIV-uninfected high-risk adults."
},
{
"nct": "NCT00112112",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "FluMist in immunocompromised children with cancer; placebo was allantoic fluid with sucrose-phosphate-glutamate buffer (excipients, no antigen)."
},
{
"nct": "NCT00119067",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG003",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG004",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG005"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"anthrax"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Pooled all AVA route/schedule groups against saline placebo; AVA is adsorbed protective-antigen filtrate (aluminium hydroxide)."
},
{
"nct": "NCT00127803",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG003",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"c_difficile"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Pooled three toxoid doses; placebo called vaccine diluent, record gives no adjuvant in it."
},
{
"nct": "NCT00128219",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"group_b_strep"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Control was Td vaccine (active control)."
},
{
"nct": "NCT00133575",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG005",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG006"
],
"placebo_content": "inert",
"offspring": false,
"background": "Dryvax smallpox vaccine at about day 180"
}
],
"targets": [
"smallpox_mpox"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Pooled MVA doses and routes against saline; all participants got Dryvax at about day 180, inside the AE window."
},
{
"nct": "NCT00157950",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"hpv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Placebo described only as matching Gardasil."
},
{
"nct": "NCT00158756",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "Tritanrix-HepB (DTPw-HBV)"
},
{
"vaccine_groups": [
{
"id": "EG002",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "Zilbrix (DTPw-HBV Kft)"
}
],
"targets": [
"rotavirus"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Rotarix vs Rotarix placebo, one comparison per co-administered DTPw-HBV product; left out EG004 (Triple Antigen + Engerix-B, no Rotarix or placebo). Open-label for the DTPw-HBV part."
},
{
"nct": "NCT00166517",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"rotavirus"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": ""
},
{
"nct": "NCT00197054",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"malaria"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Control was Rabipur rabies vaccine (active control)."
},
{
"nct": "NCT00199901",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "NY-ESO-1 melanoma vaccine vs ISCOMATRIX adjuvant alone."
},
{
"nct": "NCT00201448",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"cmv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Control labelled placebo was hepatitis A vaccine (active control)."
},
{
"nct": "NCT00212888",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [
"hiv"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Therapeutic HIV vaccination (Remune, ALVAC) in HIV-infected patients on ART before treatment interruption."
},
{
"nct": "NCT00214461",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG003",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"c_difficile"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Pooled three toxoid doses; placebo called vaccine diluent buffer, record gives no adjuvant in it."
},
{
"nct": "NCT00223080",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector",
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "adjuvant",
"offspring": false,
"background": "none"
}
],
"targets": [
"hiv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "ALVAC-HIV (canarypox vector) prime plus AIDSVAX B/E gp120 in aluminium hydroxide; placebo was ALVAC carrier without virus plus aluminium hydroxide."
},
{
"nct": "NCT00224484",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG001",
"platforms": [
"inactivated"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"herpes_simplex",
"hepatitis_a"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "gD2-AS04 (EG000) and Havrix (EG001, the trial's active control) each against saline (EG002); left out EG003 (same gD2 participants in extended follow-up) and EG004 (pools Havrix and saline)."
},
{
"nct": "NCT00231179",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Home-visiting behavioral intervention, no vaccine."
},
{
"nct": "NCT00231816",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"zoster"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Both arms got Zostavax and influenza vaccine; only timing differs."
},
{
"nct": "NCT00239577",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"dengue"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Pooled three formulations against placebo; 17b and 19 groups also got a booster without a placebo counterpart, covered only by the SAE window."
},
{
"nct": "NCT00241644",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "routine EPI vaccines"
}
],
"targets": [
"rotavirus"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Took the 2-dose and 3-dose Rotarix groups; left out EG002, which pools the same participants again."
},
{
"nct": "NCT00244374",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"hepatitis_a",
"hepatitis_b"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "All arms got hepatitis A/B vaccine; trial compares delivery and adherence support."
},
{
"nct": "NCT00258154",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "Infanrix hexa"
}
],
"targets": [
"rotavirus"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": ""
},
{
"nct": "NCT00263666",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "Tritanrix-HepB/Hib and oral polio vaccine"
}
],
"targets": [
"rotavirus"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "HIV-infected infants."
},
{
"nct": "NCT00270205",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "DermaVir therapeutic HIV DNA vaccine in people with HIV on HAART."
},
{
"nct": "NCT00273910",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "gp100 melanoma peptide vaccine with adjuvants; no placebo either."
},
{
"nct": "NCT00275262",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Leuprolide vs placebo for immune recovery after stem cell transplant; KLH immunization given to all."
},
{
"nct": "NCT00287469",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "adjuvant",
"offspring": false,
"background": "none"
}
],
"targets": [
"hepatitis_e"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Placebo was PBS containing alum."
},
{
"nct": "NCT00289341",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Autologous dendritic-cell prostate cancer vaccine."
},
{
"nct": "NCT00290355",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "MAGE-A3 cancer immunotherapeutic in resected NSCLC."
},
{
"nct": "NCT00294047",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "adjuvant",
"offspring": false,
"background": "none"
}
],
"targets": [
"hpv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Cervarix (AS04) vs aluminium hydroxide control."
},
{
"nct": "NCT00303069",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"s_aureus"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Pooled V710 doses against saline; V710 (IsdB protein) is formulated on Merck's aluminium adjuvant."
},
{
"nct": "NCT00308061",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"malaria"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Control was Imovax rabies vaccine (active control)."
},
{
"nct": "NCT00310856",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"meningococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Every arm got MenACWY-CRM; open-label schedule comparison."
},
{
"nct": "NCT00313911",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"tetanus_diphtheria_pertussis",
"hepatitis_b",
"polio",
"other"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Control was Tritanrix-HepB/Hib plus OPV (active control). Other target: Haemophilus influenzae type b."
},
{
"nct": "NCT00314132",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"japanese_encephalitis"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "ChimeriVax-JE vs 0.9% saline."
},
{
"nct": "NCT00314145",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"japanese_encephalitis"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Control was JE-VAX (active control); saline only filled schedule gaps."
},
{
"nct": "NCT00316303",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"hepatitis_a",
"hepatitis_b"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Twinrix within a behavioral package vs enhanced usual care, no placebo."
},
{
"nct": "NCT00316524",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"smallpox_mpox"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Randomized vaccinia-naive groups: two doses and one dose plus placebo against two Tris-buffer placebos; left out EG003 (vaccinia-experienced, not randomized, no placebo)."
},
{
"nct": "NCT00319098",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Control was Fluarix seasonal vaccine plus placebo (active control)."
},
{
"nct": "NCT00319592",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"japanese_encephalitis"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Control was JE-VAX (active control); saline only filled schedule gaps."
},
{
"nct": "NCT00322231",
"eligible": false,
"exclusion_reason": "groups_not_randomized_arms",
"comparisons": [],
"targets": [
"zoster"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Crossover; AE groups pool both periods by product received, so each participant is in both groups and no first-period groups are reported."
},
{
"nct": "NCT00325819",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Acetaminophen vs placebo after routine vaccines every child received."
},
{
"nct": "NCT00329745",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"rotavirus"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Year-3 extension of the primary study, groups by original randomization; only AEs leading to withdrawal were collected."
},
{
"nct": "NCT00329901",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"polysaccharide"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "Tdap vaccine"
}
],
"targets": [
"meningococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "MenACWY-CRM vs saline, both with Tdap; left out EG002 (MenACWY + saline), since EG000 can serve only one comparison and MenACWY is the trial's focus."
},
{
"nct": "NCT00339040",
"eligible": false,
"exclusion_reason": "groups_not_randomized_arms",
"comparisons": [],
"targets": [
"hpv"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Placebo arm crossed over to QHPV at week 96 and the AE groups run to study completion; no group covers only the placebo-controlled period."
},
{
"nct": "NCT00344032",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"hpv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Cervarix (AS04); placebo composition not given."
},
{
"nct": "NCT00345878",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"hpv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Cervarix (AS04); placebo composition not given."
},
{
"nct": "NCT00346398",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Oral allergen immunoprophylaxis for allergy and asthma."
},
{
"nct": "NCT00350337",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"dengue"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Pooled three formulations against EMEM/stabilizer placebo; post-transfection F17 and F19 groups also got a booster without a placebo counterpart, inside the groups."
},
{
"nct": "NCT00362648",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"rotavirus"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Took the all-randomized groups (SAEs 14 days); left out EG002-EG003 (cross-treated, mix arms) and EG004-EG005 (Kenya subset of the same participants, 42-day follow-up)."
},
{
"nct": "NCT00365378",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"hpv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Monovalent HPV 16 VLP (Merck, aluminium adjuvant); left out EG002 (extension, mixes arms)."
},
{
"nct": "NCT00365716",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG003",
"EG004"
],
"placebo_content": "adjuvant",
"offspring": false,
"background": "none"
}
],
"targets": [
"hpv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Pooled three qHPV formulations against two aluminium-adjuvant placebos; left out EG005 (extensions, mixes arms)."
},
{
"nct": "NCT00370682",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"dengue"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Two formulations of WRAIR live attenuated tetravalent dengue vaccine pooled; placebo is sterile buffer."
},
{
"nct": "NCT00378560",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"hpv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Gardasil (aluminium adjuvant); placebo composition not given."
},
{
"nct": "NCT00381615",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"meningococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Open-label; rMenB +/- OMV groups compared with routine-vaccines-only groups (who got rMenB later), no placebo."
},
{
"nct": "NCT00382408",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"other"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Target is adenovirus types 4 and 7 (other). Oral live adenovirus 4/7 tablets (live replicating, enteric; coded live_attenuated as the nearest live-vaccine category). Placebo tablets, composition not given."
},
{
"nct": "NCT00396630",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"rotavirus"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Rotarix vs placebo, 2 doses; both groups could get a complimentary Rotarix dose at week 13 (study end); AE time frame not stated, took the arm groups as reported."
},
{
"nct": "NCT00397891",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Bapineuzumab, a monoclonal antibody for Alzheimer's disease."
},
{
"nct": "NCT00397943",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG003",
"platforms": [
"protein"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG004"
],
"placebo_content": "adjuvant",
"offspring": false,
"background": "none"
}
],
"targets": [
"tuberculosis"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Control got the adjuvant system alone (which one, AS01B or AS02A, not stated). Vaccine groups: M72/AS01B, M72/AS02A, Mtb72F/AS02A (labeled active comparator but a TB candidate the control didn't get), and non-adjuvanted M72 in saline."
},
{
"nct": "NCT00409188",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Tecemotide (L-BLP25), a cancer vaccine in NSCLC."
},
{
"nct": "NCT00411749",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"hpv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Gardasil (aluminium adjuvant); placebo unspecified."
},
{
"nct": "NCT00418574",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Abagovomab, an anti-idiotype antibody for ovarian cancer."
},
{
"nct": "NCT00420316",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"rotavirus"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Long-term follow-up (6 months in third year of life, SAEs only) of the Rota-036 randomized Rotarix and placebo arms; no further vaccination, groups kept by original randomization."
},
{
"nct": "NCT00420745",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"rotavirus"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Rotarix vs placebo in pre-term infants (patients=true for prematurity)."
},
{
"nct": "NCT00423046",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"hpv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Cervarix vs Gardasil (active comparator); placebo doses only kept the blind."
},
{
"nct": "NCT00432380",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "routine infant EPI vaccines"
}
],
"targets": [
"rotavirus"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Two Rotarix liquid schedules (each with one placebo dose) pooled vs 3 doses of placebo."
},
{
"nct": "NCT00434577",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"zoster"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Every group got gE vaccine: EG003 got saline then gE/AS01B HD (AE period spans both); EG004, titled Placebo Group, got a modified gE formulation reconstituted with saline. No clean placebo group."
},
{
"nct": "NCT00435812",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"hepatitis_b"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "HEPLISAV vs Engerix-B (active comparator); saline only replaced HEPLISAV's third dose."
},
{
"nct": "NCT00437021",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG005",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG006",
"EG007",
"EG008",
"EG009",
"EG010"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"smallpox_mpox"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "IMVAMUNE (MVA against smallpox) and Dryvax (live vaccinia) groups, by schedule, pooled vs saline placebo subgroups of each schedule (no Placebo C group reported). Groups D and E got both MVA and Dryvax."
},
{
"nct": "NCT00439335",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "H5N1 vaccine ID vs IM; saline only in the other arm to keep the blind, both groups vaccinated."
},
{
"nct": "NCT00442169",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG005",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG000",
"EG004"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"other"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Target is West Nile virus (other). ChimeriVax-WN02, a live chimeric attenuated virus; Part 1 doses and Part 2 pooled with both parts' saline placebo groups."
},
{
"nct": "NCT00456807",
"eligible": false,
"exclusion_reason": "other",
"comparisons": [],
"targets": [
"hpv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Ancillary immunogenicity study of Cervarix vs placebo recipients from a primary study; the record says no safety data were collected here."
},
{
"nct": "NCT00460525",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"malaria"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "FMP2.1/AS02A vs rabies vaccine (active control)."
},
{
"nct": "NCT00464334",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "V950, an amyloid-beta vaccine for Alzheimer's disease."
},
{
"nct": "NCT00468858",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"dengue"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Two WRAIR live attenuated tetravalent dengue formulations pooled; placebo is a lyophilized product reconstituted with sterile water, contents not given."
},
{
"nct": "NCT00479557",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "ACC-001 (vanutide cridificar), an amyloid-beta vaccine for Alzheimer's disease."
},
{
"nct": "NCT00480324",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"rotavirus"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Rotarix vs placebo, 2 doses."
},
{
"nct": "NCT00481767",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "adjuvant",
"offspring": false,
"background": "none"
}
],
"targets": [
"hpv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Cervarix (AS04) vs Al(OH)3 placebo."
},
{
"nct": "NCT00485134",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG003",
"platforms": [
"protein"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG004"
],
"placebo_content": "inert",
"offspring": false,
"background": "Shigella challenge ~42 days after last dose"
}
],
"targets": [
"shigella_etec"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Took Stage 2 immunized vs controls (control given by the same nasal device; placebo described as sterile saline). Stage 1 dose groups left out: no Stage 1 placebo group is reported. Invaplex 50 (Ipa proteins with LPS) coded protein, no added adjuvant."
},
{
"nct": "NCT00485732",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"hpv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Cervarix (AS04) vs placebo of unstated composition."
},
{
"nct": "NCT00492557",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"polysaccharide"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "trivalent inactivated influenza vaccine"
}
],
"targets": [
"pneumococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Took the first period only (13vPnC+TIV vs placebo+TIV); second-period groups (EG001, EG003) are after crossover and count the same participants again."
},
{
"nct": "NCT00493285",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001",
"EG003",
"EG005"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"rsv",
"other"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Other target: parainfluenza virus type 3. MEDI-534 is a live attenuated chimeric bovine/human PIV3 carrying RSV F (coded live_attenuated as a chimeric attenuated virus). Three dose cohorts pooled with their placebo subgroups."
},
{
"nct": "NCT00496626",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "adjuvant",
"offspring": false,
"background": "none"
}
],
"targets": [
"hpv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Gardasil vs aluminium-containing placebo."
},
{
"nct": "NCT00498602",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "ACC-001, an amyloid-beta vaccine for Alzheimer's disease."
},
{
"nct": "NCT00503009",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Asthma inhalers (fluticasone/salmeterol) vs placebo with rhinovirus inoculation; no vaccine."
},
{
"nct": "NCT00508651",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"other"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Target is parainfluenza virus type 3 (other). MEDI-560 live attenuated rHPIV3cp45 vs sucrose phosphate buffer placebo."
},
{
"nct": "NCT00518336",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"hpv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Long-term follow-up (SAEs only, to year 9) of Cervarix and placebo arms of a primary study; no vaccination in this study, groups by original randomization."
},
{
"nct": "NCT00518687",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"s_aureus"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "V710 (recombinant IsdB protein, lyophilized formulation) vs matching placebo in patients scheduled for cardiothoracic surgery; adjuvant not stated in the record."
},
{
"nct": "NCT00521586",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"polysaccharide"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG006"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "trivalent inactivated influenza vaccine"
}
],
"targets": [
"pneumococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Planned crossover: took the dose 1 groups only (13vPnC+TIV vs placebo+TIV, 1 month after dose 1); later groups follow the crossover to 13vPnC and the year 5 revaccination."
},
{
"nct": "NCT00529399",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "GAD-alum (Diamyd), an antigen-specific immunotherapy for type 1 diabetes."
},
{
"nct": "NCT00534248",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"zoster"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Zostavax vs placebo of the vaccine's stabilizer without live virus."
},
{
"nct": "NCT00535236",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"inactivated"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"inactivated"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"inactivated"
],
"adjuvant": "none"
},
{
"id": "EG006",
"platforms": [
"inactivated"
],
"adjuvant": "none"
},
{
"id": "EG008",
"platforms": [
"inactivated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001",
"EG003",
"EG005",
"EG007",
"EG009"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"zoster"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "V212 heat-treated (inactivated) VZV vaccine vs placebo in immunocompromised adults (autologous HCT, allogeneic HCT, solid tumor, hematologic malignancy, HIV); population subgroups pooled."
},
{
"nct": "NCT00535730",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"zoster",
"pneumococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Zostavax with PPV23 concomitantly vs non-concomitantly; both groups got both vaccines, placebo only kept the schedule blind."
},
{
"nct": "NCT00538512",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"inactivated"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Two vaccines (Fluzone TIV IM, FluMist LAIV intranasal) against one saline placebo group, given as nasal spray or IM injection and reported as one group."
},
{
"nct": "NCT00539981",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "FluBlok recombinant HA (lots pooled) vs normal saline."
},
{
"nct": "NCT00541970",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"hpv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Cervarix formulations and schedules compared; placebo doses only filled schedule slots."
},
{
"nct": "NCT00546078",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"hpv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Open-label: former vaccinees got a 4th Cervarix dose, former placebo recipients 3 doses; no placebo in this study."
},
{
"nct": "NCT00546819",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"zoster"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Zostavax vs placebo in people on chronic/maintenance corticosteroids."
},
{
"nct": "NCT00550745",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"zoster"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Zostavax vs placebo; only SAEs collected (to 182 days)."
},
{
"nct": "NCT00555893",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Oseltamivir vs placebo for influenza treatment; no vaccine."
},
{
"nct": "NCT00562484",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"inactivated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "CSL split-virion inactivated influenza vaccine (2008 or 2009 Southern Hemisphere formulation) vs placebo of unstated composition."
},
{
"nct": "NCT00566345",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"inactivated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Vero cell-derived split-virus trivalent non-adjuvanted vaccine vs phosphate-buffered saline."
},
{
"nct": "NCT00572910",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG005",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG006",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG007",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG008",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG009",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG010"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"s_aureus"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "V710 (IsdB) groups, split by Day 180 dose (V710 or placebo), pooled; together they count each participant once. MAA (Merck aluminium adjuvant) groups coded aluminium, groups without MAA none. Hemodialysis patients."
},
{
"nct": "NCT00574704",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "House dust mite allergen vaccine with CYT003-QbG10 (allergy immunotherapy)."
},
{
"nct": "NCT00586339",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "adjuvant",
"offspring": false,
"background": "none"
}
],
"targets": [
"hpv"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Cervarix vs Al(OH)3 control in HIV-positive women; HIV-negative Cervarix group (EG002) left out, no placebo group in that population."
},
{
"nct": "NCT00596271",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG002",
"platforms": [
"inactivated"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "Havrix (hepatitis A vaccine)"
}
],
"targets": [
"japanese_encephalitis"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Took IC51+Havrix vs Havrix+placebo (placebo in place of both IC51 doses). EG000 (IC51+placebo) left out: its only clean match (Havrix vs placebo on IC51) would reuse EG002. IC51 (Ixiaro) is inactivated JE vaccine on aluminium hydroxide."
},
{
"nct": "NCT00605085",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"inactivated"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "adjuvant",
"offspring": false,
"background": "none"
}
],
"targets": [
"japanese_encephalitis"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "IC51 (inactivated JE vaccine, aluminium hydroxide) vs PBS with 0.1% aluminium hydroxide."
},
{
"nct": "NCT00616928",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"inactivated"
],
"adjuvant": "other"
},
{
"id": "EG002",
"platforms": [
"inactivated"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG001",
"EG003"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "GSK H5N1 monovalent adjuvanted vaccine (split, AS03-adjuvanted Q-Pan; formulations A-C pooled), age cohorts 18-64 and >64 pooled. Only these four groups are reported."
},
{
"nct": "NCT00620815",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Every arm got H5N1 vaccine (Aflunov) and/or MF59-eTIV-H5N1 across the study; placebo only accompanied a vaccine on day 1, and AE groups cover the whole study."
},
{
"nct": "NCT00621322",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG003",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG004",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG005",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "adjuvant",
"offspring": false,
"background": "none"
}
],
"targets": [
"tuberculosis"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Control got AS01B alone. GSK692342 (M72) formulations pooled: F1 non-adjuvanted (labeled active comparator); F2-F4 adjuvanted, adjuvant system not named per formulation, coded other (GSK692342 is M72/AS01)."
},
{
"nct": "NCT00622843",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"pneumococcal"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Open-label PCV vs PPV23 in HIV; HIV-negative PCV group; no placebo."
},
{
"nct": "NCT00630331",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Cell culture-derived and egg-derived subunit (surface antigen) influenza vaccines vs PBS; SAEs only."
},
{
"nct": "NCT00644059",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "MF59-adjuvanted TIV vs non-adjuvanted TIV vs non-influenza control vaccines (MenC conjugate or TBE); all controls are active vaccines."
},
{
"nct": "NCT00659789",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [
"hiv"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Vacc-4x is a therapeutic HIV peptide vaccine given to HIV-infected people on ART."
},
{
"nct": "NCT00661713",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"meningococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Schedule comparison of rMenB+OMV NZ; every arm, including rMenB6 (placebo months 0-2), gets the vaccine, and the AE groups span the whole study."
},
{
"nct": "NCT00677820",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Intranasal live attenuated trivalent influenza vaccine; placebo is sucrose-phosphate buffer (with egg allantoic fluid per the AE group)."
},
{
"nct": "NCT00679172",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG004"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"typhoid"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Oral live attenuated S. Typhi ZH9, four dose cohorts pooled against pooled excipient placebo."
},
{
"nct": "NCT00686075",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated",
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"live_attenuated",
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"live_attenuated",
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG006",
"platforms": [
"live_attenuated",
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG008",
"platforms": [
"live_attenuated",
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001",
"EG003",
"EG005",
"EG007",
"EG009"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"rsv",
"other"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "MEDI-534 is a live attenuated chimeric bovine/human PIV3 that also carries RSV F, so both platforms listed; other target = parainfluenza virus type 3. Five dose/age cohorts pooled."
},
{
"nct": "NCT00693654",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Pramoxine lotion for uremic itch; no vaccine."
},
{
"nct": "NCT00696709",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"inactivated"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"inactivated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"zoster"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Part 1 only (heat-treated and gamma-irradiated V212 vs placebo). Part 2 groups EG003 and EG004 left out: Part 2 had no placebo arm. V212 is inactivated VZV without adjuvant."
},
{
"nct": "NCT00702221",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Angiotensin therapeutic vaccine for hypertension, a non-infectious target."
},
{
"nct": "NCT00706550",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"pneumococcal"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Immediate vs delayed PPV23 with placebo crossover in HIV-infected adults; both arms get PPV23 and the AE groups are reported for the whole study, not the first period."
},
{
"nct": "NCT00707967",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG001",
"EG002"
],
"placebo_content": "adjuvant",
"offspring": false,
"background": "none"
}
],
"targets": [
"tuberculosis"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "M72/AS01E in HIV-positive adults. Two placebo groups: EG001 is AS01E adjuvant alone, EG002 is saline; both put in one comparison (the vaccine group can't be in two), placebo_content set to adjuvant because one placebo holds it."
},
{
"nct": "NCT00718237",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"rotavirus"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "RotaTeq vs matching placebo in Japanese infants."
},
{
"nct": "NCT00719043",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Every group, including the naive placebo-first group, receives H5N1 vaccine during the study; the AE groups span the whole study, so the Day 0-182 placebo-controlled period is not reported separately."
},
{
"nct": "NCT00723489",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"yellow_fever"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "YFV-17D subcutaneous vs transcutaneous, each with a placebo at the other site; every group gets the vaccine."
},
{
"nct": "NCT00735644",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"japanese_encephalitis"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "JE-CV lots compared with another JE-CV and a hepatitis A vaccine (Avaxim) control; no placebo."
},
{
"nct": "NCT00735839",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"s_aureus"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "V710 (IsdB protein) vs saline in healthy Japanese men; the record does not state an adjuvant."
},
{
"nct": "NCT00736476",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"other"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"other"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Target is Helicobacter pylori (preventive, in H. pylori-negative adults). Platform 'other': the record names only an investigational Novartis H. pylori vaccine, composition and adjuvant not given. Placebo composition not stated."
},
{
"nct": "NCT00744263",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"polysaccharide"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"pneumococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Took the safety set groups (all participants, SAEs to 1 month); the immunogenicity subset groups EG002 and EG003 report a subset of the same participants again and are left out. PCV13 holds aluminium phosphate."
},
{
"nct": "NCT00746798",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"other"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "ChimeriVax-WN02, a live attenuated chimeric yellow fever/West Nile virus; other target = West Nile virus. Three doses pooled vs saline."
},
{
"nct": "NCT00751777",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"shigella_etec"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Transcutaneous ETEC heat-labile toxin (LT) patch vs the same patch with 0 ug LT; no separate adjuvant. AE time frame not given."
},
{
"nct": "NCT00752232",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "ACC-001 amyloid-beta vaccine for Alzheimer's disease."
},
{
"nct": "NCT00772954",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"c_difficile"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Alum-adsorbed C. difficile toxoid vaccine, two doses pooled, vs vaccine diluent buffer."
},
{
"nct": "NCT00777257",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"meningococcal",
"tetanus_diphtheria_pertussis"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Menactra and Tdap given together or a month apart; every group gets both vaccines within the AE period."
},
{
"nct": "NCT00779402",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Sipuleucel-T, an autologous cellular vaccine for prostate cancer."
},
{
"nct": "NCT00779766",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"hpv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Cervarix (AS04, aluminium) vs placebo of unstated composition in Chinese women."
},
{
"nct": "NCT00788151",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"dengue"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Control group got two placebo injections and Pneumo23 as its third injection; the AE groups span all three, so the control is partly an active vaccine."
},
{
"nct": "NCT00800605",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"inactivated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Vero cell-derived split trivalent influenza vaccine vs PBS."
},
{
"nct": "NCT00802464",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG003",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"zoster"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "gE/AS01 formulations pooled vs saline."
},
{
"nct": "NCT00808028",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG003",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"meningococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Groups repeat participants by period; took the Stage 1 vaccination-period groups EG000-EG003, which hold every randomized participant once. Stage 1 follow-up (EG004-EG007) and Stage 2 (EG008-EG010, no 60 mcg arm) left out. rLP2086 holds aluminium phosphate."
},
{
"nct": "NCT00819013",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "M2e influenza A vaccine with Alhydrogel, with QS-21, or without adjuvant, vs saline."
},
{
"nct": "NCT00822757",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"s_aureus"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Lyophilized V710 (IsdB protein) vs buffered saline; the record does not state an adjuvant."
},
{
"nct": "NCT00834106",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "adjuvant",
"offspring": false,
"background": "none"
}
],
"targets": [
"hpv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Gardasil vs an aluminium-containing placebo."
},
{
"nct": "NCT00836498",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"rotavirus"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "RotaTeq 3 doses vs matching placebo in elderly people; the Part II one-dose RotaTeq arm has no AE group of its own."
},
{
"nct": "NCT00841763",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "TIV then aH5N1 vs placebo then aTIV; the control group gets an active adjuvanted influenza vaccine within the AE period."
},
{
"nct": "NCT00842530",
"eligible": false,
"exclusion_reason": "groups_not_randomized_arms",
"comparisons": [],
"targets": [
"dengue"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "The control AE group pools Cohort 1 (rabies vaccine then placebo) with Cohort 2 (placebo only), so the placebo-only arm isn't reported on its own."
},
{
"nct": "NCT00848211",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [
"hiv"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "TUTI-16 given to people already infected with HIV-1: a therapeutic HIV vaccine."
},
{
"nct": "NCT00849680",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG005",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG006",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG007",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"hiv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "MRKAd5 gag and gag/pol/nef doses and schedules pooled vs placebo in healthy adults. AE time frame not given."
},
{
"nct": "NCT00851786",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"zoster"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Zostavax vs placebo in HIV-infected adults on ART."
},
{
"nct": "NCT00857311",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"hiv"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Preventive MRKAd5 HIV-1 gag vaccine vs placebo in people with chronic hepatitis C; the 1x10^10 and Td arms enrolled no one."
},
{
"nct": "NCT00857493",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"smallpox_mpox"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "IMVAMUNE twice vs placebo then IMVAMUNE; both groups are vaccinated and the AE groups span the study."
},
{
"nct": "NCT00865566",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"dna",
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"hiv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "DNA prime then rAd5 boost vs PBS and final formulation buffer placebos."
},
{
"nct": "NCT00869778",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [
"hepatitis_b"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "epsilonPA-44 therapeutic hepatitis B vaccine for chronic hepatitis B."
},
{
"nct": "NCT00873912",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Intranasal live attenuated monovalent B influenza vaccine vs sucrose-phosphate buffer."
},
{
"nct": "NCT00875524",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"dengue"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Control group got meningococcal A+C polysaccharide, placebo, then Typhim Vi; active controls within the AE period."
},
{
"nct": "NCT00877448",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG006",
"platforms": [
"protein"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
},
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG005",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "adjuvant",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Multimeric-001 in PBS vs PBS, and Montanide-adjuvanted Multimeric-001 vs Montanide-adjuvanted PBS, kept as two comparisons since each pair differs only in the antigen and the placebos differ in content."
},
{
"nct": "NCT00879762",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"smallpox_mpox"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "High vs standard dose IMVAMUNE; placebo only fills out the schedule."
},
{
"nct": "NCT00879814",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"meningococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Control got Tdap at month 0 and saline at months 2 and 6; an active vaccine within the AE period."
},
{
"nct": "NCT00880698",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001",
"EG003"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"rotavirus"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "RotaTeq vs placebo in HIV-infected and HIV-uninfected infants of HIV-infected mothers; HIV strata pooled."
},
{
"nct": "NCT00880893",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"dengue"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Control group got placebo at month 0, then hepatitis A or influenza vaccine at months 6 and 12; the AE groups span all three."
},
{
"nct": "NCT00886613",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"inactivated"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "VZV skin tests and intradermal saline"
}
],
"targets": [
"zoster"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "V212 (inactivated VZV) and Zostavax each vs one placebo, so both are vaccine groups."
},
{
"nct": "NCT00920218",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"zoster"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "gE/AS01 formulations pooled; EG002 (saline then two F1 doses) counted as a vaccine group with a different schedule. Placebo is saline."
},
{
"nct": "NCT00925548",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Tecemotide (L-BLP25), a cancer vaccine for breast cancer."
},
{
"nct": "NCT00929526",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"hpv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Follow-up of Cervarix vs Aimmugen (hepatitis A vaccine) control; no placebo and no vaccination in this study."
},
{
"nct": "NCT00941889",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [
"hpv"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Gardasil given to HIV-positive patients treated for anal condylomata to prevent recurrence, i.e. against disease they already have; adverse events were also not collected."
},
{
"nct": "NCT00943878",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "H1N1 vaccine and TIV given in different orders; every group gets both."
},
{
"nct": "NCT00945893",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG004",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG005"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Groups repeat participants by period (Days 1-15, 29-57, 58-209); took Days 58-209 as the longest placebo-controlled follow-up."
},
{
"nct": "NCT00946101",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG004",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG005"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Groups repeat participants by period (Days 1-28, 29-57, 58-209); took Days 58-209 as the longest placebo-controlled follow-up."
},
{
"nct": "NCT00950612",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"tuberculosis"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "M72/AS01E vs physiological saline in healthy adolescents."
},
{
"nct": "NCT00952276",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"inactivated"
],
"adjuvant": "unknown"
},
{
"id": "EG001",
"platforms": [
"inactivated"
],
"adjuvant": "unknown"
},
{
"id": "EG002",
"platforms": [
"inactivated"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"inactivated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG004"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Subvirion H1N1 vaccine with an unnamed adjuvant (EG000, EG001, adjuvant unknown) or without (EG002, EG003) vs saline."
},
{
"nct": "NCT00952419",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"inactivated"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"inactivated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Unadjuvanted subvirion H1N1 vaccine, two doses pooled, vs saline in children."
},
{
"nct": "NCT00953056",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001",
"EG003",
"EG005"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"rotavirus"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "RotaTeq vs matching placebo; adult, child and infant cohorts pooled."
},
{
"nct": "NCT00953524",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"inactivated"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"inactivated"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"inactivated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Unadjuvanted subvirion H1N1 vaccine, three doses pooled, vs saline."
},
{
"nct": "NCT00953927",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"tuberculosis"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "MVA85A vs Candida skin test antigen (Candin), which the record calls a placebo control but is an active antigen product, neither inert nor adjuvant alone."
},
{
"nct": "NCT00958126",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"inactivated"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"inactivated"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"inactivated"
],
"adjuvant": "none"
},
{
"id": "EG005",
"platforms": [
"inactivated"
],
"adjuvant": "none"
},
{
"id": "EG006",
"platforms": [
"inactivated"
],
"adjuvant": "none"
},
{
"id": "EG007",
"platforms": [
"inactivated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG000",
"EG004"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Adult and older-adult cohorts pooled into one comparison; placebo is vaccine diluent. CSL425 taken as unadjuvanted split H1N1 vaccine (no adjuvant named)."
},
{
"nct": "NCT00958243",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"inactivated"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"inactivated"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"inactivated"
],
"adjuvant": "none"
},
{
"id": "EG005",
"platforms": [
"inactivated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG000",
"EG003"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Age cohorts A and B pooled into one comparison. Placebo composition not given."
},
{
"nct": "NCT00959192",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "ACC-001 is an anti-amyloid vaccine for Alzheimer's disease (QS-21 adjuvant control)."
},
{
"nct": "NCT00960115",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Tecemotide is a therapeutic cancer vaccine for NSCLC."
},
{
"nct": "NCT00968890",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Both arms get two doses of Pandemrix and one of Fluarix; placebo only shifts when Fluarix is given."
},
{
"nct": "NCT00969228",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"rotavirus"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Placebo composition not given."
},
{
"nct": "NCT00969878",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "TA-CD is a cocaine vaccine for treating cocaine dependence."
},
{
"nct": "NCT00971425",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Both arms get Pandemrix twice and Fluarix once; placebo only changes when Fluarix is given."
},
{
"nct": "NCT00974818",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Intravesical BCG given as bladder cancer treatment against mitomycin C; no placebo."
},
{
"nct": "NCT00975507",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"measles_mumps_rubella",
"varicella"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "ProQuad (+ placebo dummy) against licensed M-M-R II + Varivax: active control."
},
{
"nct": "NCT00981175",
"eligible": false,
"exclusion_reason": "groups_not_randomized_arms",
"comparisons": [],
"targets": [
"japanese_encephalitis"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Planned crossover (vaccine then diluent vs diluent then vaccine at Day 28); AE groups cover both periods (6 months), so the first, placebo-controlled period isn't reported alone. EG002 is a booster group."
},
{
"nct": "NCT00981630",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"japanese_encephalitis"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Three dose levels pooled; ChimeriVax-JE is a chimeric live attenuated virus; placebo is ChimeriVax diluent."
},
{
"nct": "NCT00981669",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"rotavirus"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Butantan rotavirus vaccine in adults; record doesn't name its platform, taken as live oral rotavirus vaccine. Placebo composition not given."
},
{
"nct": "NCT00982137",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"japanese_encephalitis",
"yellow_fever"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Every arm gets both ChimeriVax-JE and STAMARIL; arms differ only in order and co-administration; AE groups span both visits."
},
{
"nct": "NCT00985088",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Every arm gets an H1N1 vaccine; saline only replaces a second dose."
},
{
"nct": "NCT00985166",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG002",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "M-M-R II"
}
],
"targets": [
"varicella"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Clean comparison is Varivax vs placebo, both with M-M-R II (EG002 vs EG001). EG000 (ProQuad + placebo) left out: ProQuad replaces M-M-R II, an active comparison."
},
{
"nct": "NCT00985426",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"hepatitis_b"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "HEPLISAV-B against licensed Engerix-B in chronic kidney disease; saline only blinds the schedule."
},
{
"nct": "NCT00985673",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Every arm gets Flulaval and two doses of Arepanrix (adjuvanted or not); saline only shifts timing."
},
{
"nct": "NCT00992433",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Two dose levels of H1N1 vaccine in HIV-infected adults; no placebo arm."
},
{
"nct": "NCT00993447",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"dengue"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Control got NaCl at months 0 and 6 but Adacel at month 12, and the AE groups span all three injections, so the control group isn't a clean placebo group."
},
{
"nct": "NCT00993668",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [
"influenza",
"pneumococcal"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Tests certolizumab pegol's effect on influenza and pneumococcal vaccine responses in rheumatoid arthritis; every arm gets the vaccines."
},
{
"nct": "NCT00995865",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"inactivated"
],
"adjuvant": "aluminium"
},
{
"id": "EG001",
"platforms": [
"inactivated"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"yellow_fever"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Groups are reported per injection; took the first-injection groups (EG000-EG002), which count every randomized participant once; second-injection groups EG003-EG005 left out (same participants). Placebo is 0.9% NaCl."
},
{
"nct": "NCT00996125",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"hpv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Cervarix holds AS04 (aluminium hydroxide + MPL). Placebo composition not given."
},
{
"nct": "NCT01001325",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"inactivated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Fluviral is an unadjuvanted split seasonal vaccine; placebo is normal saline."
},
{
"nct": "NCT01005407",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"hepatitis_b"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "HEPLISAV against licensed Engerix-B; saline only blinds the third visit."
},
{
"nct": "NCT01009645",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Behavioral trial of educational messages on influenza vaccine uptake; no vaccine is given as an intervention."
},
{
"nct": "NCT01009762",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "AFO-18 is a therapeutic HIV peptide vaccine in chronic HIV infection."
},
{
"nct": "NCT01011335",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG003",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG004",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG005",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG006",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG007",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG008",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG009",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG010",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG011",
"EG012"
],
"placebo_content": "adjuvant",
"offspring": false,
"background": "none"
}
],
"targets": [
"s_aureus"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Two placebo groups pooled: EG011 is alum placebo, EG012 is saline; placebo_content set to adjuvant for the alum group. Vaccine's alum not stated outright, inferred from the 'placebo with adjuvant' arm. Recombinant toxoids rAT and rLukS-PV."
},
{
"nct": "NCT01015443",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Tecemotide is a therapeutic cancer vaccine for NSCLC."
},
{
"nct": "NCT01017536",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"tuberculosis"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "AERAS-402 is an Ad35 vector; placebo is its formulation buffer. HIV-infected, BCG-vaccinated adults."
},
{
"nct": "NCT01035749",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Every arm gets Arepanrix (adjuvanted or not); saline only replaces a dose."
},
{
"nct": "NCT01047345",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"hpv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Took base-study groups; EG002 (open-label 9vHPV in the extension, former placebo recipients) left out. V503 holds AAHS; placebo is saline."
},
{
"nct": "NCT01051661",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Every arm gets an H1N1 vaccine; placebo only replaces a second dose."
},
{
"nct": "NCT01059617",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG004",
"platforms": [
"inactivated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG005"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Took the pooled Day 0 groups, Flulaval (EG004) vs saline (EG005), the placebo-controlled period. EG000-EG003 left out: the same participants again, for the period when every arm got Arepanrix."
},
{
"nct": "NCT01067781",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
},
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "skin swabbing before patch"
}
],
"targets": [
"shigella_etec"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Transcutaneous patch of E. coli heat-labile enterotoxin (LT) against ETEC travelers' diarrhea. Split by skin swabbing, which both sides of each pair got. Placebo patch composition not given."
},
{
"nct": "NCT01080716",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"shigella_etec"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Took Part 1 (WRSS1 vs placebo). Part 2 challenge groups EG002 (vaccinees, same participants) and EG003 (naive controls) left out."
},
{
"nct": "NCT01104493",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Monovalent intranasal FluMist; placebo is the sucrose phosphate/gelatin-arginine-glutamate buffer."
},
{
"nct": "NCT01134263",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG004"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"dengue"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Four CYD-TDV lots pooled; placebo is NaCl 0.9%."
},
{
"nct": "NCT01141205",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "AFO-18 therapeutic HIV peptide vaccine in HIV-infected people (CDC group I) to prevent progression to disease."
},
{
"nct": "NCT01144637",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"smallpox_mpox"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Three IMVAMUNE (MVA-BN) lots pooled; placebo is Tris-buffered saline."
},
{
"nct": "NCT01147068",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG004",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG005",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG006",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Recombinant H5N1 hemagglutinin (PanBlok) at several doses, with or without GLA-SE (TLR4 agonist in oil-in-water emulsion, no aluminium), against 0.9% saline; doses pooled into one comparison."
},
{
"nct": "NCT01150123",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"other"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"other"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"other"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"other"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"other"
],
"adjuvant": "aluminium"
},
{
"id": "EG005",
"platforms": [
"other"
],
"adjuvant": "aluminium"
},
{
"id": "EG006",
"platforms": [
"other"
],
"adjuvant": "aluminium"
},
{
"id": "EG007",
"platforms": [
"other"
],
"adjuvant": "aluminium"
},
{
"id": "EG009",
"platforms": [
"other"
],
"adjuvant": "other"
},
{
"id": "EG010",
"platforms": [
"other"
],
"adjuvant": "other"
},
{
"id": "EG011",
"platforms": [
"other"
],
"adjuvant": "other"
},
{
"id": "EG012",
"platforms": [
"other"
],
"adjuvant": "other"
},
{
"id": "EG013",
"platforms": [
"other"
],
"adjuvant": "other"
},
{
"id": "EG014",
"platforms": [
"other"
],
"adjuvant": "other"
},
{
"id": "EG015",
"platforms": [
"other"
],
"adjuvant": "other"
},
{
"id": "EG016",
"platforms": [
"other"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG008",
"EG017"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"group_b_strep"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Platform 'other': the record doesn't say what the GBS vaccine is (protein or conjugate). Doses, 1 or 2 injections, and no-adjuvant/alum/MF59 formulations pooled with both saline placebo groups."
},
{
"nct": "NCT01151189",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"tuberculosis"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "MVA85A (MVA carrying Ag85A). Placebo is Candin, a Candida albicans skin-test antigen: not inert and not an adjuvant, so set to not_stated. HIV-infected adults."
},
{
"nct": "NCT01165177",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"zoster"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "gE/AS01B (Shingrix); placebo is NaCl solution."
},
{
"nct": "NCT01165203",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"zoster"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "gE/AS01B in HIV-infected adults. Placebo composition not given."
},
{
"nct": "NCT01165229",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"zoster"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "gE/AS01B (Shingrix); placebo is NaCl solution."
},
{
"nct": "NCT01168401",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG003",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG005",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG007",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG009",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG004",
"EG006",
"EG008",
"EG010"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"norovirus"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "VLP vaccine with MPL + Al(OH)3; cohorts A-D (doses and ages) pooled with their saline placebo groups."
},
{
"nct": "NCT01171963",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "routine infant vaccines (Infanrix, OPV)"
}
],
"targets": [
"rotavirus"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Liquid Rotarix vs placebo, both with EPI Infanrix and OPV. Placebo composition not given."
},
{
"nct": "NCT01173653",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Smoking-cessation counseling trial in emergency department patients; no vaccine."
},
{
"nct": "NCT01181323",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "LAIV vs TIV in postpartum breastfeeding women, double-dummy placebos; active control. Infant groups likewise have no placebo."
},
{
"nct": "NCT01187433",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"dengue"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Arm and AE group say the control got 3 injections of NaCl 0.9%, but the control arm's intervention list also names Adacel and meningococcal A+C vaccine without saying when; taken as placebo per the AE group description. A second reader should check this."
},
{
"nct": "NCT01193920",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"other"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
},
{
"vaccine_groups": [
{
"id": "EG002",
"platforms": [
"other"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"other"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"other"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG005"
],
"placebo_content": "inert",
"offspring": false,
"background": "pregnancy and antenatal care"
},
{
"vaccine_groups": [
{
"id": "EG006",
"platforms": [
"other"
],
"adjuvant": "none"
},
{
"id": "EG007",
"platforms": [
"other"
],
"adjuvant": "none"
},
{
"id": "EG008",
"platforms": [
"other"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG009"
],
"placebo_content": "inert",
"offspring": true,
"background": "none"
}
],
"targets": [
"group_b_strep"
],
"off_target": false,
"pregnant": true,
"patients": false,
"note": "Non-pregnant women (alum, 2 doses) and pregnant women (unadjuvanted, 1 dose) kept as separate comparisons since pregnancy and its care differ; infants of the pregnant women are the offspring comparison. Platform 'other': trivalent GBS vaccine, type not stated (likely capsular polysaccharide conjugate). Placebo is saline."
},
{
"nct": "NCT01198366",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG000",
"EG005"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"tuberculosis"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Dose-finding (2 doses) and expanded safety phase (3 doses) pooled; placebo is sterile buffer. Infants had BCG before the study."
},
{
"nct": "NCT01199861",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [
"influenza",
"tetanus_diphtheria_pertussis"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Tests fingolimod's effect on responses to influenza and tetanus vaccines that every arm gets, in multiple sclerosis."
},
{
"nct": "NCT01203319",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"hepatitis_b"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "60, 30 and 10 mcg hepatitis B vaccine in prior non-responders; the 'placebo comparator' is the 10 mcg vaccine."
},
{
"nct": "NCT01214837",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"meningococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Open-label MenACWY-CRM + routine vaccines vs routine vaccines alone; no placebo."
},
{
"nct": "NCT01214850",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"meningococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Control is Japanese encephalitis vaccine (IXIARO), an active control; placebo only fills MenACWY's second visit."
},
{
"nct": "NCT01218113",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Therapeutic HIV vaccine in ART-naive HIV-infected people."
},
{
"nct": "NCT01224639",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG006",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001",
"EG003",
"EG005",
"EG007"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"dengue"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "TDV (TAK-003 precursor) low/high dose by SC/ID route pooled with their PBS placebo groups."
},
{
"nct": "NCT01227564",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "ACC-001 anti-amyloid vaccine for Alzheimer's disease."
},
{
"nct": "NCT01229267",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"inactivated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"zoster"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Inactivated VZV vaccine V212, all lots pooled as reported; placebo is the vaccine stabilizer without antigen, so taken as unadjuvanted."
},
{
"nct": "NCT01245764",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"hpv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Placebo arm exists only in the 9-12 year cohort; took Gardasil 9-12 (EG000) vs placebo 9-12 (EG003). Gardasil 13-15 and 16-26 (EG001, EG002) left out: no placebo in their age cohorts. Gardasil holds amorphous aluminium hydroxyphosphate sulfate."
},
{
"nct": "NCT01254422",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"dengue"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "CYD-TDV vs NaCl 0.9%."
},
{
"nct": "NCT01254630",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"inactivated"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"inactivated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG002",
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"zoster"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Pooled solid-tumour and haematologic-malignancy strata. V212 is inactivated VZV (heat-inactivated Zostavax), no adjuvant; placebo is the vaccine stabilizer without antigen."
},
{
"nct": "NCT01262976",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG004",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG001",
"EG003",
"EG005"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"tuberculosis"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Pooled HIV+ on HAART, HIV+ HAART-naive and HIV- strata. GSK692342 is the M72 fusion protein with AS01 (record names only the code)."
},
{
"nct": "NCT01263691",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG003",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG004",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG005"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"anthrax"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "BioThrax (AVA, aluminium hydroxide) and four AV7909 formulations (AVA + CpG 7909) all against saline; BioThrax included as a second vaccine against the same placebo. Record says other-AE frequency thresholds used all arms combined."
},
{
"nct": "NCT01264601",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Both arms get TIV; compares single dose vs graded challenge in egg-allergic children."
},
{
"nct": "NCT01265433",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "WT-1 peptide cancer vaccine in mesothelioma; control is Montanide + GM-CSF."
},
{
"nct": "NCT01272180",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"meningococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "All groups get meningococcal vaccines; MenACWY group got placebo then MenACWY, and AE groups cover the whole period."
},
{
"nct": "NCT01274897",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"polysaccharide"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"meningococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "MenACWY-CRM (CRM197 conjugate, no adjuvant) vs saline."
},
{
"nct": "NCT01280552",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Dendritic-cell glioblastoma vaccine."
},
{
"nct": "NCT01280903",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Behavioural physical-activity intervention, no vaccine."
},
{
"nct": "NCT01280968",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Anti-nicotine (addiction) vaccine vs alum placebo."
},
{
"nct": "NCT01299480",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"meningococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "All five groups get rLP2086 on different schedules, saline only filling visits."
},
{
"nct": "NCT01310413",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"inactivated"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Took pooled blinded-phase groups EG000 vs EG001. EG002 (placebo recipients vaccinated in the unblinded phase) left out as post-crossover. GSK H5N1 split-virion vaccine with AS03."
},
{
"nct": "NCT01322490",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "PROSTVAC prostate cancer vaccine."
},
{
"nct": "NCT01323270",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "Repevax (Tdap-IPV) at month 0"
}
],
"targets": [
"meningococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Bivalent rLP2086 (aluminium phosphate) vs saline, both with Repevax."
},
{
"nct": "NCT01326546",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Therapeutic hepatitis B vaccine with entecavir in chronic HBV."
},
{
"nct": "NCT01335191",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [
"hiv"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "TUTI-16 in HIV-1-infected people on ART with a treatment interruption: a therapeutic HIV vaccine."
},
{
"nct": "NCT01352793",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"meningococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Control is Havrix (active vaccine) with one saline dose."
},
{
"nct": "NCT01352845",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"meningococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Bivalent rLP2086 (aluminium phosphate) vs saline."
},
{
"nct": "NCT01359150",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [
"influenza",
"pneumococcal"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Tests tofacitinib vs placebo for its effect on influenza and pneumococcal vaccines that every arm receives (could also be coded vaccine_in_every_arm)."
},
{
"nct": "NCT01367158",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"meningococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Extension: third dose of meningococcal vaccine vs Tdap as control; no placebo group."
},
{
"nct": "NCT01373281",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"dengue"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "CYD-TDV vs NaCl 0.9%."
},
{
"nct": "NCT01374516",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"dengue"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "CYD-TDV vs NaCl 0.9%."
},
{
"nct": "NCT01385566",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"zoster"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Every group gets Zostavax; the Placebo group (EG006) is the saline-injected limb of vaccinated participants."
},
{
"nct": "NCT01411241",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"dengue"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Both groups get CYD; only Pentaxim timing differs."
},
{
"nct": "NCT01424501",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG004",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG001",
"EG003",
"EG005"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"tuberculosis"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Pooled TB-treatment, TB-treated and TB-naive cohorts. Safety study of a preventive candidate (M72/AS01, named only GSK692342) in people with current or past TB disease, not given as treatment."
},
{
"nct": "NCT01424644",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"polysaccharide"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "Tdap (Boostrix) and HPV (Gardasil)"
}
],
"targets": [
"meningococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "MenACWY-CRM vs placebo, both with Tdap and qHPV."
},
{
"nct": "NCT01436357",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"other"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Other = hepatitis C (prophylactic ChAd3-NSmut prime, MVA-NSmut boost). Placebo is sodium chloride. Analysed as treated."
},
{
"nct": "NCT01436396",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"dengue"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Placebo group gets placebo only at injection 1 and CYD at months 6 and 12, inside the reported AE period; no placebo-only groups."
},
{
"nct": "NCT01446289",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"polysaccharide"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
},
{
"vaccine_groups": [
{
"id": "EG002",
"platforms": [
"polysaccharide"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "inert",
"offspring": true,
"background": "none"
}
],
"targets": [
"group_b_strep"
],
"off_target": false,
"pregnant": true,
"patients": false,
"note": "Mothers EG000 vs EG001; infants EG002 vs EG003 as offspring. Trivalent GBS conjugate; adjuvant not stated."
},
{
"nct": "NCT01447407",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"protein"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "adjuvant",
"offspring": false,
"background": "none"
}
],
"targets": [
"s_aureus",
"other"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Other = Candida (NDV-3, rAls3 protein). Arm and intervention say the placebo is alum in PBS; the AE group calls it saline given ID. Coded adjuvant by the arm description."
},
{
"nct": "NCT01461096",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"hpv"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "qHPV vs placebo in HIV-infected adults."
},
{
"nct": "NCT01461980",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "MCV4 and Tdap at month 0"
}
],
"targets": [
"meningococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "rLP2086 vs saline, both with MCV4+Tdap. EG002 (rLP2086 with saline in place of MCV4+Tdap, given those at month 7) left out."
},
{
"nct": "NCT01461993",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "inert",
"offspring": false,
"background": "Gardasil at months 0, 2, 6"
}
],
"targets": [
"meningococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Took rLP2086 vs saline on a Gardasil background (EG000 vs EG002). EG001 (rLP2086 + saline) left out: EG000 can serve only one comparison; the alternative was Gardasil vs saline on rLP2086 (EG000 vs EG001)."
},
{
"nct": "NCT01462357",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"hpv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Cervarix vs Gardasil schedules; placebo only fills a visit."
},
{
"nct": "NCT01489020",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "House-dust-mite allergen immunotherapy."
},
{
"nct": "NCT01489527",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"hiv",
"hpv"
],
"off_target": true,
"pregnant": false,
"patients": false,
"note": "Gardasil vs placebo tested to reduce HIV infection (off target), also its own HPV target."
},
{
"nct": "NCT01501162",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Probiotics in alcoholic hepatitis; no vaccine, and AEs not collected."
},
{
"nct": "NCT01505166",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Autologous tumour-cell (Vigil/FANG) cancer vaccine."
},
{
"nct": "NCT01507779",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"inactivated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Whole-virion inactivated H1N1 (IVACFLU) vs PBS; formulation given in full with no adjuvant, coded none."
},
{
"nct": "NCT01509846",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"inactivated"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"inactivated"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"inactivated"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"inactivated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG004"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"shigella_etec"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Pooled four dose cohorts of oral killed whole-cell S. flexneri 2a vs pooled placebo; no adjuvant in the record, coded none."
},
{
"nct": "NCT01511250",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG006",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG008",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001",
"EG003",
"EG005",
"EG007",
"EG009"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"dengue"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Pooled Part I age cohorts and Part II. TAK-003 (TDV) vs matching placebo."
},
{
"nct": "NCT01511419",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Groups are reported per dose for the same participants; took the dose-1 groups (all randomized participants), left out dose-2 groups EG002, EG003. Placebo is saline passed through eggs like the vaccine."
},
{
"nct": "NCT01527383",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"inactivated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"zoster"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "V212 inactivated VZV (no adjuvant) vs placebo in adults with autoimmune disease."
},
{
"nct": "NCT01529645",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"tetanus_diphtheria_pertussis"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "All groups get aP or Tdap formulations; saline only fills a visit."
},
{
"nct": "NCT01537185",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"inactivated"
],
"adjuvant": "aluminium"
},
{
"id": "EG002",
"platforms": [
"inactivated"
],
"adjuvant": "aluminium"
},
{
"id": "EG003",
"platforms": [
"inactivated"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"pneumococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Inactivated whole-cell pneumococcal vaccine with alum, three doses, vs saline."
},
{
"nct": "NCT01542632",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"dengue"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "All groups get TDV on different schedules or formulations."
},
{
"nct": "NCT01545375",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "Prevnar 13 (and PedvaxHIB in a subset)"
}
],
"targets": [
"pneumococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "dPly-PhtD protein vaccine vs placebo, both with Prevnar 13; adjuvant not stated."
},
{
"nct": "NCT01546571",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Melanoma vaccine."
},
{
"nct": "NCT01550289",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"dengue"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "CYD-TDV vs NaCl 0.9%."
},
{
"nct": "NCT01567306",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Grass-pollen allergen immunotherapy."
},
{
"nct": "NCT01570036",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "E75 HER2 peptide cancer vaccine with trastuzumab."
},
{
"nct": "NCT01579916",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Intranasal cold-adapted attenuated 6:2 reassortant trivalent vaccine vs sucrose-phosphate buffer placebo."
},
{
"nct": "NCT01609257",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "experimental norovirus GII.4 challenge"
}
],
"targets": [
"norovirus"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Bivalent norovirus VLP with MPL and Al(OH)3 vs saline, both followed by challenge."
},
{
"nct": "NCT01610414",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"zoster"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "GSK1437173A (Shingrix, gE/AS01B) vs saline. Record names no condition for enrolment, so patients false."
},
{
"nct": "NCT01616693",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [
"rotavirus",
"polio"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Tests zinc and probiotic supplements on Rotarix and OPV that every arm receives (could also be coded vaccine_in_every_arm)."
},
{
"nct": "NCT01625689",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "SII intranasal LAIV vs placebo of identical ingredients without virus."
},
{
"nct": "NCT01662440",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"inactivated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "JE vaccine on days 1 and 29"
}
],
"targets": [
"rabies"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "R/JE-Conv (EG000) vs JE-Conv (EG003) differ only in rabies vaccine (Rabipur-type, inactivated) vs saline. EG000 can serve one comparison; the alternative was JE vs saline on rabies (EG000 vs EG002). EG001 (accelerated schedule) and EG002 left out."
},
{
"nct": "NCT01666652",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"inactivated"
],
"adjuvant": "aluminium"
},
{
"id": "EG001",
"platforms": [
"inactivated"
],
"adjuvant": "aluminium"
},
{
"id": "EG002",
"platforms": [
"inactivated"
],
"adjuvant": "other"
},
{
"id": "EG003",
"platforms": [
"inactivated"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG004"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"dengue"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "TDENV-PIV with alum (1 and 4 ug), AS01E or AS03B vs PBS."
},
{
"nct": "NCT01682876",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"meningococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "One vs two MenACWY-CRM doses; all get vaccine. EG004 is a total."
},
{
"nct": "NCT01687595",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Therapeutic HSV-2 vaccine (HerpV + QS-21) in recurrent genital herpes."
},
{
"nct": "NCT01694108",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"other"
],
"off_target": true,
"pregnant": false,
"patients": false,
"note": "BCG at birth given for its non-specific effect on childhood morbidity (target 'other': general childhood morbidity and infections, not tuberculosis). Control children got no intervention ('no suitable placebo exists')."
},
{
"nct": "NCT01697800",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Tadalafil vs placebo in head and neck cancer; no vaccine."
},
{
"nct": "NCT01704781",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [
"hiv"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Vacc-4x is a therapeutic HIV vaccine given to HIV-infected people on ART; every arm gets it and the trial tests lenalidomide vs placebo."
},
{
"nct": "NCT01719783",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Groups reported per dose; took the Dose 1 groups (EG000, EG001), which include every randomized participant; Dose 2 groups re-count them."
},
{
"nct": "NCT01723254",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Anti-IgE vaccine for allergic rhinitis: non-infectious target."
},
{
"nct": "NCT01733056",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Every group gets Fluzone; groups are healthy volunteers vs patients on immunosuppressants, pre/post vaccination, not randomized to placebo."
},
{
"nct": "NCT01734811",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"other"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"other"
],
"off_target": true,
"pregnant": false,
"patients": true,
"note": "Sublingual bacterial vaccine spray in toddlers with recurrent wheezing (bronchiolitis/bronchitis); target 'other' = recurrent wheezing attacks/respiratory infections. Platform 'other': polybacterial preparation, composition not given in the record. Judged a preventive vaccine rather than an immune stimulant; off_target because it is a bacterial vaccine given against wheezing attacks."
},
{
"nct": "NCT01739231",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"live_attenuated"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"shigella_etec"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Took Part A groups (EG000-EG002). Part B challenge groups (EG003-EG005) re-count Part A participants, and EG005 adds controls not randomized in Part A. EG001 got ACE527 with dmLT, a mucosal adjuvant, kept as the vaccine's adjuvant ('other'). Placebo is CeraVacx buffer (rice syrup, bicarbonate, citrate), the vaccine's buffer."
},
{
"nct": "NCT01745822",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": true,
"patients": true,
"note": "Tenofovir vs placebo in HBV-infected pregnant women; infants' HBV immunization is background in both arms."
},
{
"nct": "NCT01755598",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"tuberculosis"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "M72/AS01E (AS01 adjuvant)."
},
{
"nct": "NCT01764256",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"rotavirus"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Saline placebo."
},
{
"nct": "NCT01765426",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"dengue"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "All four groups get TDV; PBS placebo only fills in doses to compare schedules and devices."
},
{
"nct": "NCT01767467",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"zoster"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "HZ/su (Shingrix, AS01B) in adults with haematologic malignancies."
},
{
"nct": "NCT01773395",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "GVAX leukaemia cell vaccine: cancer vaccine."
},
{
"nct": "NCT01777295",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"hepatitis_b"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "HBsAg/AS vs Engerix-B (active control); the Day -30 placebo dose is given to both groups."
},
{
"nct": "NCT01797029",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Placebo is the LAIV's ingredients with the viruses replaced by egg allantoic fluid; coded inert (excipients, no antigen)."
},
{
"nct": "NCT01798056",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"zoster"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "HZ/su (Shingrix, AS01B) in adults with solid tumours on chemotherapy."
},
{
"nct": "NCT01802086",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"pneumococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "EMLA vs placebo cream for pain at a pneumococcal vaccination every infant gets."
},
{
"nct": "NCT01813071",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG005",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG006",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG007",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG003",
"EG008"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"shigella_etec"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Live oral S. sonnei WRSS1; adult and child cohorts and doses pooled into one comparison with each part's placebo group."
},
{
"nct": "NCT01824537",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"hpv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Control is Avaxim (hepatitis A vaccine, active control) with a saline dose added to match the schedule."
},
{
"nct": "NCT01825200",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Flublok vs Afluria (licensed IIV, active control) despite the 'Placebo Comparator' label."
},
{
"nct": "NCT01830855",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"meningococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Control got Havrix (hepatitis A vaccine) plus one saline dose: active control."
},
{
"nct": "NCT01842360",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"inactivated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"other"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "MV130 (Bactek), sublingual polyvalent whole-cell inactivated bacterial vaccine, in COPD; target 'other' = COPD exacerbations/respiratory bacterial infections. Platform and no adjuvant from what is known of MV130, not stated in the record."
},
{
"nct": "NCT01854632",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Placebo is the LAIV's ingredients with the viruses replaced by egg allantoic fluid; coded inert."
},
{
"nct": "NCT01859143",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Intranasal trivalent vaccine dosed in FFU: live attenuated influenza vaccine."
},
{
"nct": "NCT01859325",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [
"hiv"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Therapeutic HIV vaccine (HIV-MAG pDNA + IL-12 pDNA prime, rVSV boost) in HIV-infected patients on ART."
},
{
"nct": "NCT01862874",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "adjuvant",
"offspring": false,
"background": "none"
}
],
"targets": [
"hpv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Gardasil (AAHS); placebo formulated with AAHS adjuvant."
},
{
"nct": "NCT01865487",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG003",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG005",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG000",
"EG004"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"tuberculosis"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "H56:IC31 (IC31 adjuvant); 2-dose and 3-dose schedules and their placebo groups pooled. Placebo is Tris-NaCl buffer. Participants with and without latent TB infection, not enrolled for a disease, so patients false."
},
{
"nct": "NCT01877655",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"dna"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"cmv"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Record calls ASP0113 a 'therapeutic vaccine' but it is given to CMV-seropositive HCT recipients to prevent CMV reactivation disease (protective efficacy), like zoster vaccines in VZV carriers, so kept as preventive. Platform (plasmid DNA) and adjuvant (poloxamer CRL1005 with benzalkonium chloride) from what is known of ASP0113, not in the record."
},
{
"nct": "NCT01887912",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"c_difficile"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Sanofi C. difficile toxoid vaccine; aluminium hydroxide adjuvant from what is known of the product, not stated in the record. Enrolled adults at risk of C. difficile infection (impending hospitalization or recent hospital stays with antibiotics), so patients true."
},
{
"nct": "NCT01892345",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Eculizumab (antibody) vs placebo in NMO."
},
{
"nct": "NCT01895855",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "Vibrio cholerae challenge 10 days or 3 months after vaccination"
}
],
"targets": [
"cholera"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "PXVX0200 (CVD 103-HgR) vs saline; both arms challenged."
},
{
"nct": "NCT01900665",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Solanezumab (passive immunization, antibody) in Alzheimer's disease."
},
{
"nct": "NCT01922921",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "HER2 peptide cancer vaccine in every arm; trial tests polysaccharide-K vs placebo."
},
{
"nct": "NCT01926028",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "adjuvant",
"offspring": false,
"background": "none"
}
],
"targets": [
"other"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Target 'other' = recurrent vulvovaginal candidiasis (Candida). Kept as preventive: given to prevent recurrences, not to treat a current infection. Placebo is aluminium hydroxide in buffered saline."
},
{
"nct": "NCT01928225",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [
"hpv"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "qHPV given to HIV-infected women with cervical HSIL to improve the response to LEEP treatment: used against a lesion they already have (HPV-lesion use)."
},
{
"nct": "NCT01949090",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"inactivated"
],
"adjuvant": "unknown"
},
{
"id": "EG001",
"platforms": [
"inactivated"
],
"adjuvant": "unknown"
},
{
"id": "EG002",
"platforms": [
"inactivated"
],
"adjuvant": "unknown"
},
{
"id": "EG003",
"platforms": [
"inactivated"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG004"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "GSK H7N1 vaccine, four formulations whose content the record does not give; coded inactivated (GSK's IM influenza vaccines are split virion), adjuvant unknown."
},
{
"nct": "NCT01973218",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"meningococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Control got saline at Day 1 and MenACWY-CRM at Day 31, and the groups report Days 1-61 as a whole, so the control group includes an active vaccine; EG002 is a total."
},
{
"nct": "NCT01974206",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"dna"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"cmv"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "ASP0113 in CMV-seronegative kidney recipients of seropositive organs. Platform (plasmid DNA) and adjuvant (poloxamer CRL1005 with benzalkonium chloride) from what is known of ASP0113, not in the record."
},
{
"nct": "NCT01981616",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"hepatitis_b",
"cholera"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Vedolizumab vs placebo; both arms get HBVAXPRO and Dukoral."
},
{
"nct": "NCT01982331",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Placebo is a lyophilizate of the vaccine's stabilizers."
},
{
"nct": "NCT01986010",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"other"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"other"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"other"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"other"
],
"adjuvant": "aluminium"
},
{
"id": "EG004",
"platforms": [
"other"
],
"adjuvant": "none"
},
{
"id": "EG006",
"platforms": [
"other"
],
"adjuvant": "none"
},
{
"id": "EG008",
"platforms": [
"other"
],
"adjuvant": "none"
},
{
"id": "EG009",
"platforms": [
"other"
],
"adjuvant": "none"
},
{
"id": "EG010",
"platforms": [
"other"
],
"adjuvant": "aluminium"
},
{
"id": "EG011",
"platforms": [
"other"
],
"adjuvant": "none"
},
{
"id": "EG012",
"platforms": [
"other"
],
"adjuvant": "aluminium"
},
{
"id": "EG013",
"platforms": [
"other"
],
"adjuvant": "none"
},
{
"id": "EG015",
"platforms": [
"other"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG005",
"EG007",
"EG014",
"EG016"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"cmv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Platform 'other': V160 is a replication-defective whole-virus HCMV vaccine (from what is known of it; record names only V160). Serostatus strata, doses, routes (IM/ID) and MAPA formulations pooled with all four placebo groups; MAPA groups aluminium, others none."
},
{
"nct": "NCT01989572",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Melanoma peptide vaccine and GM-CSF: cancer."
},
{
"nct": "NCT01992536",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein",
"polysaccharide"
],
"adjuvant": "aluminium"
},
{
"id": "EG002",
"platforms": [
"protein",
"polysaccharide"
],
"adjuvant": "aluminium"
},
{
"id": "EG004",
"platforms": [
"protein",
"polysaccharide"
],
"adjuvant": "aluminium"
},
{
"id": "EG005",
"platforms": [
"protein",
"polysaccharide"
],
"adjuvant": "aluminium"
},
{
"id": "EG007",
"platforms": [
"protein",
"polysaccharide"
],
"adjuvant": "aluminium"
},
{
"id": "EG008",
"platforms": [
"protein",
"polysaccharide"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG001",
"EG003",
"EG006",
"EG009"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"meningococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Extension of V102_03: participants randomized again to a booster or saline; the tables report only this later randomization, so it is used. Priming strata pooled; EG010 (total) left out. MenABCWY = rMenB+OMV (aluminium hydroxide, as in Bexsero) plus MenACWY-CRM conjugate."
},
{
"nct": "NCT01997229",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Eculizumab (antibody) in myasthenia gravis."
},
{
"nct": "NCT02010203",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "HS-410 bladder cancer cell vaccine; BCG given as bladder cancer therapy."
},
{
"nct": "NCT02017899",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"other"
],
"adjuvant": "aluminium"
},
{
"id": "EG001",
"platforms": [
"other"
],
"adjuvant": "aluminium"
},
{
"id": "EG002",
"platforms": [
"other"
],
"adjuvant": "aluminium"
},
{
"id": "EG003",
"platforms": [
"other"
],
"adjuvant": "aluminium"
},
{
"id": "EG004",
"platforms": [
"other"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG005"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"shigella_etec"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Platform 'other': 1790GAHB is a GMMA (outer membrane vesicle) S. sonnei vaccine; aluminium hydroxide (Alhydrogel) from what is known of the product, not in the record."
},
{
"nct": "NCT02041325",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"hepatitis_b"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Lenalidomide vs placebo around a hepatitis B vaccine every patient gets."
},
{
"nct": "NCT02046148",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"polysaccharide"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"group_b_strep"
],
"off_target": false,
"pregnant": true,
"patients": false,
"note": "Maternal groups only (control is normal saline despite 'Active Comparator' label); no separate infant groups are reported, though the time frame includes infant SAEs, so no offspring comparison. Adjuvant not stated."
},
{
"nct": "NCT02058589",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"zoster"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "HZ/su (AS01B) in renal transplant recipients; placebo is lyophilised sucrose in saline."
},
{
"nct": "NCT02062385",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "routine infant vaccines (OPV, DTaP), staggered or concomitant"
}
],
"targets": [
"rotavirus"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "RotaTeq; each group pools the staggered and concomitant EPI arms."
},
{
"nct": "NCT02071095",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Poly-ICLC (immune stimulant alone) in chronic HIV infection."
},
{
"nct": "NCT02075203",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG001",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"tuberculosis"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Two vaccines against one saline placebo: H4:IC31 (IC31 adjuvant) and BCG revaccination, both tested for preventing infection; BCG kept as a vaccine group despite the 'Active Comparator' label. Placebo follows H4:IC31's 2-dose schedule; BCG is one dose."
},
{
"nct": "NCT02075541",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"other"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Target 'other' = non-typeable Haemophilus influenzae; NTHi protein vaccine with AS01E in COPD patients."
},
{
"nct": "NCT02094586",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG003",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG004"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"cholera"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Took the pooled 'All PXVX0200 Lots' group (EG003) rather than lots A-C (EG000-EG002): the same participants, and per the AE description only SAEs were analysed per lot."
},
{
"nct": "NCT02097472",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"inactivated"
],
"adjuvant": "aluminium"
},
{
"id": "EG001",
"platforms": [
"inactivated"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
},
{
"vaccine_groups": [
{
"id": "EG003",
"platforms": [
"inactivated"
],
"adjuvant": "aluminium"
},
{
"id": "EG005",
"platforms": [
"inactivated"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG007"
],
"placebo_content": "inert",
"offspring": false,
"background": "Synflorix (PCV10) and Pentavac (DTwP-HepB-Hib)"
}
],
"targets": [
"pneumococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Adults: wSP vs saline. Toddlers: wSP plus Synflorix and Pentavac vs saline plus the same vaccines. Toddler wSP+saline groups (EG004, EG006) left out: no group got saline alone to match them."
},
{
"nct": "NCT02100631",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"cholera"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Historical control arm is not in the AE groups."
},
{
"nct": "NCT02109484",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG003",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG005",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG006",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG007",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG000",
"EG004"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"rotavirus"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Toddler and infant cohorts and doses pooled with both placebo groups. Aluminium hydroxide from what is known of P2-VP8, not stated in this record."
},
{
"nct": "NCT02111577",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "DCVAC/PCa dendritic cell cancer vaccine."
},
{
"nct": "NCT02115815",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG003",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG005",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG006",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "RSV sF alone (none) and MEDI7510 (sF with GLA-SE, 'other') at three doses vs saline."
},
{
"nct": "NCT02116205",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"other"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Hantaan/Puumala DNA vaccine (target 'other' = hantavirus, HFRS) in every arm; saline only replaces the Day 28 dose to compare schedules."
},
{
"nct": "NCT02117570",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG004",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG005",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG000",
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"c_difficile"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Pfizer C. difficile toxoid vaccine, two doses, two age cohorts pooled. Aluminium hydroxide from what is known of the product, not stated in the record."
},
{
"nct": "NCT02117934",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"hepatitis_b"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "HEPLISAV vs Engerix-B, an active control; HEPLISAV's week-24 saline only fills the schedule."
},
{
"nct": "NCT02124161",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"polysaccharide"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "seasonal inactivated influenza vaccine (QIV)"
}
],
"targets": [
"pneumococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Planned crossover: took the 'After Vaccination 1' groups (Day 1 to before Vaccination 2), before the placebo arm got 13vPnC; later-period and 'after 13vPnC' groups left out. Prevnar 13 holds aluminium phosphate."
},
{
"nct": "NCT02130882",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Benralizumab, an antibody; no vaccine."
},
{
"nct": "NCT02134925",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "MUC1 peptide vaccine against colorectal adenoma and cancer, a non-infectious target."
},
{
"nct": "NCT02140762",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"meningococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Control arm got placebo then MenACWY at month 2, and the AE groups cover the whole study, so the control group includes an active meningococcal vaccine; no group for the placebo-only period is reported."
},
{
"nct": "NCT02142504",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"norovirus"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Placebo arm got the norovirus vaccine at Day 365, inside the AE window (Days 365-393, SAEs to Day 545); only whole-study groups are reported, none for the placebo-controlled first year alone."
},
{
"nct": "NCT02147587",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [
"zoster"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Tests tofacitinib vs placebo for its effect on a zoster vaccine every arm got."
},
{
"nct": "NCT02153112",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"norovirus"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Every group got the norovirus VLP vaccine; placebo only replaces a later dose (1 vs 2, or 2 vs 3 doses)."
},
{
"nct": "NCT02171819",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"inactivated"
],
"adjuvant": "aluminium"
},
{
"id": "EG001",
"platforms": [
"inactivated"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Inactivated H5N1 vaccine with aluminium hydroxide at 7.5 and 15 mcg HA, pooled, vs phosphate-buffered saline."
},
{
"nct": "NCT02187055",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Tofacitinib and adalimumab in rheumatoid arthritis; no vaccine."
},
{
"nct": "NCT02190747",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Palovarotene in FOP; no vaccine."
},
{
"nct": "NCT02193087",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"dengue"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Every group got a TDV formulation; placebo only replaces Group A's second dose."
},
{
"nct": "NCT02195349",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "GSK2831781 is an IV biologic (antibody) tested in healthy volunteers and plaque psoriasis patients, not a vaccine; the PPD skin challenge is not a vaccine either. patients true for the psoriasis cohort."
},
{
"nct": "NCT02210780",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Dupilumab vs placebo for its effect on vaccine responses; the vaccines are not named in the record."
},
{
"nct": "NCT02212457",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"meningococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Every group got a meningococcal vaccine (MenABCWY schedules or Bexsero); saline and Havrix only fill schedule slots for blinding."
},
{
"nct": "NCT02218697",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"influenza",
"pneumococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Both groups got QIV and PPV23 within the AE window (together, or PPV23 28 days later); only whole-study groups are reported."
},
{
"nct": "NCT02225587",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"pneumococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Both groups got Prevnar 13 and Pneumovax 23 in different sequences; placebo only fills a schedule slot."
},
{
"nct": "NCT02261961",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [
"tetanus_diphtheria_pertussis"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Tests a nutritional supplement vs Kool-Aid placebo; both arms got Tdap."
},
{
"nct": "NCT02269423",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"ebola"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "V920 (rVSV-ZEBOV) doses pooled; vaccine cohorts also got saline in the other deltoid, the placebo cohort saline in both."
},
{
"nct": "NCT02280408",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"ebola"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "V920 (rVSV-ZEBOV) doses pooled against saline."
},
{
"nct": "NCT02285777",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"polysaccharide",
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"meningococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Extension of a randomized parent study: the MenABCWY group got a third MenABCWY dose, the 'MenACWY Group' only placebo in this study (labelled active comparator for its parent-study MenACWY dose), so parent-study history differs. MenABCWY's MenB component is aluminium-adsorbed."
},
{
"nct": "NCT02287480",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"ebola"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "VSV-ZEBOV doses pooled, including the 3x10^5 pfu group added by amendment."
},
{
"nct": "NCT02289820",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG003",
"platforms": [
"inactivated"
],
"adjuvant": "none"
},
{
"id": "EG005",
"platforms": [
"inactivated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG002",
"EG004"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "MEDI7510 RSV sF + GLA-SE vaccine"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "MEDI7510 has no placebo: the IIV-alone arm (EG001) is not called placebo. In cohorts 2 and 3 participants were randomized to MEDI7510+IIV or MEDI7510+placebo, so the clean comparison is IIV vs placebo on a MEDI7510 background, the two cohorts' GLA doses pooled. Cohorts 1 and 4 (MEDI7510 alone) and EG001 left out."
},
{
"nct": "NCT02297698",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "NeuVax (nelipepimut-S) breast cancer vaccine vs GM-CSF, both with trastuzumab."
},
{
"nct": "NCT02298179",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG004",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG005",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG006",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG008",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG009",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG010",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG003",
"EG007",
"EG011"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Three dose cohorts, each with its own saline placebo group, and three adjuvant formulations (none, aluminium hydroxide, MF59) pooled."
},
{
"nct": "NCT02301611",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Autologous tumor lysate dendritic cell vaccine against melanoma recurrence: a cancer vaccine."
},
{
"nct": "NCT02302066",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"dengue"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "TAK-003 schedules pooled; vaccine groups got placebo at the visits without TDV. Placebo composition not given."
},
{
"nct": "NCT02314923",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG005",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG006",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG007",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG008",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG004",
"EG009"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"ebola"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "V920 doses in both cohorts pooled against both cohorts' saline placebo groups."
},
{
"nct": "NCT02315703",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector",
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG001",
"platforms": [
"viral_vector",
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG002",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"viral_vector",
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG004",
"platforms": [
"viral_vector",
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG005",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG006",
"platforms": [
"viral_vector",
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG007"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"hiv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "All seven Ad26 / MVA / gp140 (aluminium phosphate) regimens pooled against saline (Group 8). Groups 1-2's SAE window runs to week 336 through a long-term extension without placebo; other AEs cover the main study (to week 96) for all."
},
{
"nct": "NCT02316470",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"c_difficile"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "VLA84 arms are labelled active comparator but are vaccine doses; placebo is PBS."
},
{
"nct": "NCT02326805",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "PROSTVAC prostate cancer vaccine."
},
{
"nct": "NCT02340338",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG003",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG004",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG005",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG006"
],
"placebo_content": "adjuvant",
"offspring": false,
"background": "none"
}
],
"targets": [
"s_aureus"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "rTSST-1 variant is a recombinant toxoid of S. aureus toxic shock syndrome toxin-1; control is Al(OH)3 adjuvant alone, so the vaccine is taken as aluminium-adjuvanted. Doses pooled."
},
{
"nct": "NCT02344407",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"ebola"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "ChAd3-EBO Z and rVSV-ZEBOV against one saline placebo."
},
{
"nct": "NCT02362451",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "TARP peptide dendritic-cell vaccine against prostate cancer."
},
{
"nct": "NCT02366728",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "CMV pp65 dendritic-cell vaccine for glioblastoma; Td is given as injection-site preconditioning, controlled by unpulsed DCs, not by placebo."
},
{
"nct": "NCT02374814",
"eligible": false,
"exclusion_reason": "other",
"comparisons": [],
"targets": [
"rabies"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Placebo groups (albumin and saline, one dose) were followed for AEs 7 days, vaccine groups (3-4 doses) 372 days, so the groups do not cover the same period; open label."
},
{
"nct": "NCT02377349",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "inert",
"offspring": true,
"background": "none"
}
],
"targets": [
"tetanus_diphtheria_pertussis"
],
"off_target": false,
"pregnant": true,
"patients": false,
"note": "Crossover at delivery: the mother groups cover the pregnancy dose and the post-delivery dose (control mothers got Boostrix after delivery), so they are left out. Infant groups compared by their mothers' pregnancy dose (offspring); control infants' mothers got Boostrix within 72 h of birth. Household group EG004 not randomized, left out. Boostrix holds aluminium salts."
},
{
"nct": "NCT02382913",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"tetanus_diphtheria_pertussis"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Persistence extension; every group got an aP or Tdap booster in the parent study, there is no placebo group, and no AE data were collected."
},
{
"nct": "NCT02383498",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Yeast-brachyury vaccine against chordoma."
},
{
"nct": "NCT02388165",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"polysaccharide",
"protein"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"s_aureus"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "SA4Ag: two capsular polysaccharide conjugates plus ClfA and MntC proteins, lyophilized and reconstituted in water, unadjuvanted as known for the product. Placebo is excipients in water. Patients scheduled for spinal fusion surgery."
},
{
"nct": "NCT02388997",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Omalizumab vs placebo before an experimental rhinovirus challenge; no vaccine."
},
{
"nct": "NCT02396134",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"cmv"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "CMVPepVax (pp65 peptide) to prevent CMV events after allogeneic HCT, taken as preventive (like a zoster vaccine against reactivation). Adjuvant from the product: given with the TLR9 agonist PF03512676."
},
{
"nct": "NCT02404311",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector",
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"hiv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Took Part A (first randomization): ALVAC-HIV plus gp120/MF59 vs placebos (stabilizer in NaCl, and saline). Part B re-randomized vaccinees at month 30; EG002-EG004 left out."
},
{
"nct": "NCT02414828",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"tuberculosis"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "AERAS-402 (adenovirus-vectored TB vaccine) in adults who completed TB treatment, to prevent recurrence; taken as preventive. Placebo is the formulation buffer."
},
{
"nct": "NCT02415166",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"inactivated"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"inactivated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001",
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Major depression patients and healthy controls pooled; the vaccine serves as an immune challenge. The IM seasonal influenza vaccine is not named; taken as inactivated, unadjuvanted."
},
{
"nct": "NCT02415387",
"eligible": false,
"exclusion_reason": "groups_not_randomized_arms",
"comparisons": [],
"targets": [
"typhoid"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Crossover typhoid vaccine (as immune stress) vs placebo in breast cancer survivors; AE groups are by product received in either period, each participant in both, with no first-period groups."
},
{
"nct": "NCT02416453",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG003",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG005",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG007",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG009",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG004",
"EG006",
"EG008",
"EG010"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"ebola"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Ad26.ZEBOV prime with MVA-BN-Filo boost at three intervals (cohorts II-III) and Group 4's Ad26.ZEBOV alone, pooled against their saline placebo groups. Cohort I groups (EG000-EG002) had no placebo arm and are left out."
},
{
"nct": "NCT02438423",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"inactivated"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"inactivated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "TIV by microneedle patch (staff- or self-applied) vs placebo patch; the IM TIV group (EG001) is left out since no placebo was given by injection."
},
{
"nct": "NCT02450578",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "DSM265 antimalarial drug before a sporozoite challenge; no vaccine."
},
{
"nct": "NCT02453048",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"tetanus_diphtheria_pertussis"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "BPZE1 intranasal live attenuated pertussis vaccine; placebo is diluent. Non-randomized PRN-high group EG004 left out."
},
{
"nct": "NCT02459262",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG004",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG005",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG007",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG008",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG009",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG006",
"EG010"
],
"placebo_content": "adjuvant",
"offspring": false,
"background": "none"
}
],
"targets": [
"group_b_strep"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Parts A and B pooled. Part B's placebo is Alhydrogel in buffer; Part A's was Alhydrogel in buffer or buffer alone, recorded as adjuvant."
},
{
"nct": "NCT02465216",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG003",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG004"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"tuberculosis"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "ID93 + GLA-SE in HIV-negative adults after TB treatment completion, to prevent recurrence; taken as preventive. Placebo is saline."
},
{
"nct": "NCT02465268",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "CMV pp65 RNA-pulsed dendritic-cell vaccine for glioblastoma; Td given to all as a booster or skin prep."
},
{
"nct": "NCT02473510",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Intranasal live attenuated trivalent influenza vaccine vs matched placebo."
},
{
"nct": "NCT02485301",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"ebola"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Placebo group got ChAd3-EBO-Z at Month 6, inside the SAE window (to Month 12); only whole-study groups are reported."
},
{
"nct": "NCT02491463",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "ChAd155-RSV doses pooled; Bexsero active-control group EG003 left out."
},
{
"nct": "NCT02492958",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"polysaccharide",
"protein"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"polysaccharide",
"protein"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG000",
"EG002"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"s_aureus"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Two age strata pooled. SA4Ag (polysaccharide conjugates plus proteins) unadjuvanted as known for the product; placebo is its excipients."
},
{
"nct": "NCT02496897",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [
"hepatitis_b"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "FP-02.2 therapeutic peptide vaccine for chronic hepatitis B."
},
{
"nct": "NCT02503202",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG004"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"ebola"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "rVSV-ZEBOV consistency and high-dose lots pooled against saline."
},
{
"nct": "NCT02506933",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"cmv"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "CMV-MVA Triplex in CMV-seropositive HCT recipients to prevent CMV complications, taken as preventive."
},
{
"nct": "NCT02508194",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "inert",
"offspring": false,
"background": "inactivated influenza vaccine"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Placebo + IIV arm is labelled active comparator, but its control is saline placebo for MEDI7510 (sF with GLA-SE)."
},
{
"nct": "NCT02509494",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"ebola"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Controls got MenACWY (active control) then placebo; Stage 1 had no control."
},
{
"nct": "NCT02519855",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"zoster",
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Both groups got Zostavax and influenza vaccine within the AE window (together, or 4 weeks apart)."
},
{
"nct": "NCT02522949",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "ColdZyme mouth spray (device) against induced rhinovirus cold; no vaccine."
},
{
"nct": "NCT02531698",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"meningococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Control arm got licensed hepatitis A vaccine (months 0, 6) with saline only at month 2: active control."
},
{
"nct": "NCT02531802",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"inactivated"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"inactivated"
],
"adjuvant": "other"
},
{
"id": "EG003",
"platforms": [
"inactivated"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"inactivated"
],
"adjuvant": "none"
},
{
"id": "EG005",
"platforms": [
"inactivated"
],
"adjuvant": "none"
},
{
"id": "EG006",
"platforms": [
"inactivated"
],
"adjuvant": "other"
},
{
"id": "EG007",
"platforms": [
"inactivated"
],
"adjuvant": "other"
},
{
"id": "EG008",
"platforms": [
"inactivated"
],
"adjuvant": "other"
},
{
"id": "EG010",
"platforms": [
"inactivated"
],
"adjuvant": "none"
},
{
"id": "EG011",
"platforms": [
"inactivated"
],
"adjuvant": "none"
},
{
"id": "EG012",
"platforms": [
"inactivated"
],
"adjuvant": "other"
},
{
"id": "EG013",
"platforms": [
"inactivated"
],
"adjuvant": "other"
},
{
"id": "EG015",
"platforms": [
"inactivated"
],
"adjuvant": "none"
},
{
"id": "EG016",
"platforms": [
"inactivated"
],
"adjuvant": "none"
},
{
"id": "EG017",
"platforms": [
"inactivated"
],
"adjuvant": "none"
},
{
"id": "EG018",
"platforms": [
"inactivated"
],
"adjuvant": "other"
},
{
"id": "EG019",
"platforms": [
"inactivated"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG002",
"EG009",
"EG014",
"EG020"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"shigella_etec"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "ETVAX: formalin-inactivated ETEC bacteria plus LCTBA toxoid (coded inactivated, like killed oral cholera). dmLT groups coded as adjuvanted formulations (adjuvant other), not as a separate active product. Placebo is the bicarbonate buffer. All age cohorts pooled."
},
{
"nct": "NCT02534935",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"meningococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Control arm got pediatric hepatitis A vaccine (months 0, 6) with saline only at month 2: active control."
},
{
"nct": "NCT02538341",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "ongoing anti-TNF therapy"
}
],
"targets": [
"zoster"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Zostavax vs saline in anti-TNF users with inflammatory disease."
},
{
"nct": "NCT02543892",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"inactivated"
],
"adjuvant": "aluminium"
},
{
"id": "EG001",
"platforms": [
"inactivated"
],
"adjuvant": "aluminium"
},
{
"id": "EG003",
"platforms": [
"inactivated"
],
"adjuvant": "aluminium"
},
{
"id": "EG004",
"platforms": [
"inactivated"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG002",
"EG005"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"pneumococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Whole-cell inactivated pneumococcal vaccine on aluminium hydroxide; adult and toddler cohorts pooled."
},
{
"nct": "NCT02547974",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "unknown"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"other"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Target: non-typeable H. influenzae and Moraxella catarrhalis (PD, PE-PilA, UspA2 proteins). F1 is stated non-adjuvanted; F2/F3 are 'adjuvanted' with the adjuvant not named. Placebo group pools 18-40 and 50-70 year steps."
},
{
"nct": "NCT02551809",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "UB-311 is an anti-amyloid vaccine for Alzheimer's disease."
},
{
"nct": "NCT02561195",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "unknown"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "unknown"
},
{
"id": "EG003",
"platforms": [
"protein"
],
"adjuvant": "unknown"
},
{
"id": "EG004",
"platforms": [
"protein"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG002",
"EG005"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"c_difficile"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Took stage 1 groups (both schedules, both doses, saline placebo). Left out EG006-EG013: extension-stage fourth dose re-randomized among vaccine recipients only. Toxoid vaccine; adjuvant not stated."
},
{
"nct": "NCT02562482",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"chikungunya"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "CHIKV virus-like particle vaccine; adjuvant not stated. Placebo is PBS."
},
{
"nct": "NCT02564523",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG006",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG008",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG010",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG012",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG014",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG016",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001",
"EG003",
"EG005",
"EG007",
"EG009",
"EG011",
"EG013",
"EG015",
"EG017"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"ebola"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Ad26.ZEBOV prime, MVA-BN-Filo boost (both vectors) vs saline. Pooled all intervals and cohorts (healthy adults/elderly, HIV-infected adults, adolescents, children); patients true because cohort 2a enrolled HIV-infected adults. Cohort 1 third dose was also placebo-controlled."
},
{
"nct": "NCT02566265",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Both arms get influenza vaccine at day 0 (control arm's is standard of care, standard dose if <65); the trial compares a high-dose booster at day 30 with placebo."
},
{
"nct": "NCT02585700",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"inactivated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Split inactivated TIV, no adjuvant mentioned; placebo PBS."
},
{
"nct": "NCT02587221",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Control is Boostrix (Tdap), an active vaccine control despite the Placebo Comparator label."
},
{
"nct": "NCT02598089",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"inactivated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Split-virion TIV (IVACFLU-S), no adjuvant mentioned; placebo PBS."
},
{
"nct": "NCT02598388",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG006",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG008",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG010",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001",
"EG003",
"EG005",
"EG007",
"EG009",
"EG011"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"ebola"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "MVA-BN-Filo and Ad26.ZEBOV in either order vs saline; pooled both parts, both orders, healthy and HIV-infected participants (patients true for the HIV-infected groups)."
},
{
"nct": "NCT02612909",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"inactivated"
],
"adjuvant": "aluminium"
},
{
"id": "EG002",
"platforms": [
"inactivated"
],
"adjuvant": "aluminium"
},
{
"id": "EG004",
"platforms": [
"inactivated"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG000",
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Whole-virion inactivated H5N1 on aluminium hydroxide; phase 2 and phase 3 parts pooled; placebo PBS."
},
{
"nct": "NCT02623725",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "prior 3-dose CYD-TDV series in earlier trials"
}
],
"targets": [
"dengue"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "CYD-TDV booster vs saline in people who completed 3 doses in earlier studies."
},
{
"nct": "NCT02624947",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
},
{
"vaccine_groups": [
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "inert",
"offspring": true,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": true,
"patients": false,
"note": "Maternal RSV F nanoparticle vaccine with aluminium phosphate vs formulation buffer; infants as second comparison."
},
{
"nct": "NCT02628444",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"dengue"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Stage I groups all receive CYD (1, 2 or 3 doses, placebo in place of earlier doses); groups cover the whole period, so no placebo-only group; stage II is booster only."
},
{
"nct": "NCT02640716",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Cognitive training program (named 'Cog-VACCINE'); no vaccine."
},
{
"nct": "NCT02642237",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Both arms get Fluenz; the trial tests IV LPS vs placebo before it."
},
{
"nct": "NCT02646371",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"polysaccharide"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"shigella_etec"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Flexyn2a, an S. flexneri 2a O-polysaccharide bioconjugate; adjuvant not stated. Placebo TBS. Groups are the vaccination phase; both arms were later challenged with S. flexneri 2a."
},
{
"nct": "NCT02646891",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG004",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG005",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG007",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG008",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG009",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG000",
"EG003",
"EG006"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"rotavirus"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "P2-VP8 subunit on aluminium hydroxide vs saline; adult, toddler and infant cohorts pooled."
},
{
"nct": "NCT02649192",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Both arms get Fluzone; the trial tests vitamin A and D supplements vs placebo."
},
{
"nct": "NCT02660489",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "OC459 (CRTH2 antagonist drug) with rhinovirus challenge in asthma; no vaccine."
},
{
"nct": "NCT02661490",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"norovirus"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Every arm gets the norovirus VLP vaccine (1-dose arms get placebo then vaccine on day 29); compares formulations and schedules."
},
{
"nct": "NCT02669121",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"norovirus"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Bivalent norovirus VLP with aluminium hydroxide vs saline."
},
{
"nct": "NCT02678455",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"dengue"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "TV005 live attenuated tetravalent dengue vaccine; placebo composition not given."
},
{
"nct": "NCT02707692",
"eligible": false,
"exclusion_reason": "groups_not_randomized_arms",
"comparisons": [],
"targets": [
"pneumococcal",
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Three-period crossover (Pneumovax, Fluarix, saline in randomized orders) given to perturb the HIV reservoir; AE groups are by product across periods, so each participant appears in all three and no first-period groups are reported."
},
{
"nct": "NCT02708745",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Behavioral survey intervention about vaccine hesitancy; no vaccine given."
},
{
"nct": "NCT02712424",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"other"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "prior BCG"
}
],
"targets": [
"tuberculosis"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "DAR-901 composition not given in the record (it is described elsewhere as a whole-cell inactivated mycobacterial vaccine), so platform other and adjuvant unknown. Participants previously received BCG."
},
{
"nct": "NCT02717494",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"polysaccharide"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"polysaccharide"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
},
{
"vaccine_groups": [
{
"id": "EG005",
"platforms": [
"polysaccharide"
],
"adjuvant": "none"
},
{
"id": "EG006",
"platforms": [
"polysaccharide"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG007"
],
"placebo_content": "inert",
"offspring": true,
"background": "none"
}
],
"targets": [
"pneumococcal"
],
"off_target": false,
"pregnant": true,
"patients": true,
"note": "Step 1 groups only: PPV-23 (plain) and PCV-10 (licensed in Brazil, Synflorix, aluminium phosphate) vs saline in HIV-infected pregnant women; infants as second comparison. Left out EG003/EG004: placebo recipients vaccinated postpartum (step 2)."
},
{
"nct": "NCT02726178",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "All preterm infants get their primary immunizations; the trial tests ibuprofen vs placebo around them. Vaccines not named."
},
{
"nct": "NCT02738450",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "ACI-24 is an anti-amyloid vaccine (Alzheimer's prevention in Down syndrome), a non-infectious target."
},
{
"nct": "NCT02741128",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"dengue"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "CYD-TDV vs saline in HIV-positive adults."
},
{
"nct": "NCT02743117",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Monovalent intranasal cold-adapted live attenuated influenza vaccine; placebo composition not given."
},
{
"nct": "NCT02747927",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"dengue"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Tables report the same participants again by Part (1-5). Took Part 1 (EG000/EG001: vaccination period, the only part with all AEs); left out Parts 2-3 (later follow-up of the same participants; Part 3 is longer, about 3 years, but SAEs only) and Parts 4-5 (booster subset). Placebo composition not given."
},
{
"nct": "NCT02750202",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"hpv"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Quadrivalent HPV vaccine given to people with genital warts to prevent recurrence; control is hepatitis B vaccine (active control)."
},
{
"nct": "NCT02756208",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "unknown"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "unknown"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"hiv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "IHV01 (full-length single-chain gp120-CD4 complex) in HIV-uninfected adults; adjuvant not stated; placebo saline."
},
{
"nct": "NCT02788045",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector",
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG001",
"platforms": [
"viral_vector",
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"hiv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Ad26 mosaic vectors (weeks 0, 12) then Ad26 plus clade C gp140 with aluminium phosphate (weeks 24, 48) vs pooled saline placebo."
},
{
"nct": "NCT02788188",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "SAB-301 is a polyclonal antibody against MERS-CoV, not a vaccine."
},
{
"nct": "NCT02794870",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Intranasal live attenuated RSV LID dM2-2 1030s vs isotonic diluent in seronegative children."
},
{
"nct": "NCT02807623",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Every arm gets influenza vaccine; the trial tests ibuprofen, placebo, or push-ups after it."
},
{
"nct": "NCT02810340",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"meningococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Control is Menactra, an active vaccine."
},
{
"nct": "NCT02814643",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Both arms get seasonal influenza vaccine; the trial tests benralizumab vs placebo."
},
{
"nct": "NCT02814708",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG003",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG004",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG005",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG006"
],
"placebo_content": "adjuvant",
"offspring": false,
"background": "none"
}
],
"targets": [
"s_aureus"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Recombinant TSST-1 variant toxoid against staphylococcal toxic shock; control got Al(OH)3 adjuvant alone, so the vaccine's adjuvant is taken as aluminium. Groups with 1 or 2 immunizations got adjuvant for the remaining injections. All doses pooled."
},
{
"nct": "NCT02824198",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "prior 3-dose CYD-TDV series in an earlier trial"
}
],
"targets": [
"dengue"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "CYD-TDV booster vs saline in people who completed 3 doses in CYD28."
},
{
"nct": "NCT02826798",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG003",
"platforms": [
"protein"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG004"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"cmv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "CMV gB enveloped VLP, with Adju-Phos (aluminium phosphate) or without; placebo buffer/sucrose."
},
{
"nct": "NCT02839161",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"other"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Hookworm vaccines (Na-APR-1, Na-GST-1); control is hepatitis B vaccine plus saline, an active control. Target other: hookworm."
},
{
"nct": "NCT02839330",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Cell-derived H5N1 subunit vaccine with MF59 (three lots pooled in EG000) vs saline."
},
{
"nct": "NCT02852005",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "unknown"
},
{
"id": "EG003",
"platforms": [
"protein"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG000",
"EG002"
],
"placebo_content": "inert",
"offspring": false,
"background": "MVA/HIV62B boost; all previously vaccinated in HVTN 205"
}
],
"targets": [
"hiv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "AIDSVAX B/E vs saline, both arms boosted with MVA/HIV62B; pooled the two prior-regimen strata (MMM: EG001 vs EG000; DDMM: EG003 vs EG002). Left out EG004 (placebo + AIDSVAX), whose MVA-vs-placebo partner EG003 is already used. AIDSVAX adjuvant not stated."
},
{
"nct": "NCT02861586",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"chikungunya"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Every MV-CHIK group gets MV-CHIK within the AE period (placebo only replaces some doses); controls are Priorix, an active vaccine."
},
{
"nct": "NCT02873286",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG004"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "MVA-BN-RSV vs TBS placebo. Took the two-dose groups; left out EG000/EG002, whose groups include a week-56 booster phase and follow-up to 108 weeks without placebo (placebo followed 30 weeks)."
},
{
"nct": "NCT02876328",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG006",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG007",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG008",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG010",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG011",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG012",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG014",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG015",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG016",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG018",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001",
"EG005",
"EG009",
"EG013",
"EG017",
"EG019"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"ebola"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "PREVAC: Ad26.ZEBOV/MVA-BN-Filo and rVSV-ZEBOV regimens vs saline; adults and children under protocol versions 2.0-4.0 pooled."
},
{
"nct": "NCT02888756",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [
"hiv"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "iHIVARNA-01 is a therapeutic mRNA vaccine for chronically HIV-infected people on ART."
},
{
"nct": "NCT02890381",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Intranasal live attenuated RSV LID cp dM2-2 vs isotonic diluent in seronegative children."
},
{
"nct": "NCT02894840",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"inactivated"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"inactivated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001",
"EG003"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Split-virion TIV, no adjuvant mentioned; phase I and II groups pooled; placebo composition not given."
},
{
"nct": "NCT02915016",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"dna",
"protein"
],
"adjuvant": "other"
},
{
"id": "EG001",
"platforms": [
"dna",
"protein"
],
"adjuvant": "other"
},
{
"id": "EG002",
"platforms": [
"dna",
"protein"
],
"adjuvant": "other"
},
{
"id": "EG003",
"platforms": [
"dna",
"protein"
],
"adjuvant": "other"
},
{
"id": "EG004",
"platforms": [
"dna",
"protein"
],
"adjuvant": "other"
},
{
"id": "EG005",
"platforms": [
"dna",
"protein"
],
"adjuvant": "other"
},
{
"id": "EG006",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG007"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"hiv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "HIV DNA plus gp120 with MF59 or AS01B (groups 1-6) and gp120/AS01B alone (group 7), each vs the saline-only group 8."
},
{
"nct": "NCT02918006",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector"
],
"adjuvant": "other"
},
{
"id": "EG001",
"platforms": [
"inactivated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "H1N1 influenza challenge after vaccination"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Oral Ad5 HA vector tablet with dsRNA adjuvant (VXA-A1.1) and Fluzone Quadrivalent (QIV with oral placebo) each vs oral placebo tablets plus IM saline. Placebo tablets' composition not given (IM placebo was saline)."
},
{
"nct": "NCT02919306",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [
"hiv"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Therapeutic HIV vaccine (Ad26/MVA mosaic) in HIV-infected adults on ART."
},
{
"nct": "NCT02925403",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"malaria"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Only two AE groups reported: EG001 is titled 'Group 2' but its description is the saline arm, so taken as placebo; the 50 ug arm has no AE group. R21/Matrix-M1: protein, Matrix-M adjuvant."
},
{
"nct": "NCT02927873",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG003",
"EG004",
"EG005"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "ChAd155-RSV doses pooled against the three volume-matched placebo groups."
},
{
"nct": "NCT02934178",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"shigella_etec"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Only cohort 1 (3x10^3 CFU) and its placebo are reported as AE groups. Oral live attenuated Shigella sonnei WRSS1; placebo sterile saline."
},
{
"nct": "NCT02935192",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"inactivated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Split inactivated TIV, composition given without adjuvant; placebo PBS."
},
{
"nct": "NCT02935686",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector",
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG001",
"platforms": [
"viral_vector",
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"hiv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "First randomization taken (Groups 1-2 vs Group 3 main study). EG003/EG004 left out: a later re-randomization of vaccine recipients to late boost or placebo. Vaccine groups also include LTE follow-up (to Week 216) while placebo runs to Week 72."
},
{
"nct": "NCT02942277",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"malaria"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Comparator arms received Engerix-B (and Menactra), an active control vaccine; saline was only a diluent/dose filler."
},
{
"nct": "NCT02948959",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Dupilumab (monoclonal antibody) for asthma; no vaccine."
},
{
"nct": "NCT02956746",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [
"rabies"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Tests SYN023 antibody vs human rabies immune globulin; every arm gets rabies vaccine (vaccine_in_every_arm also applies)."
},
{
"nct": "NCT02956837",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "unknown"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "unknown"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "GSK3003891A dosed in ug of antigen (protein); adjuvant not stated. Placebo is formulation buffer S9b. Non-pregnant healthy women."
},
{
"nct": "NCT02958345",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"zoster"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Zostavax in adults with cirrhosis; placebo normal saline."
},
{
"nct": "NCT02962908",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"other"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
},
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"other"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "adjuvant",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Two matched designs kept apart because their placebos differ: unadjuvanted FLU-v x2 vs saline x2, and Montanide ISA-51-adjuvanted FLU-v + saline vs adjuvant-only placebo + saline. Platform 'other': the record does not say what FLU-v is (believed a synthetic peptide mix, which would be protein)."
},
{
"nct": "NCT02968849",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector",
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"hiv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "ALVAC-HIV plus bivalent gp120/MF59 vs sodium chloride."
},
{
"nct": "NCT02971670",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "adjuvant",
"offspring": false,
"background": "none"
}
],
"targets": [
"s_aureus"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Booster amendment of a Phase I trial: participants re-immunized by their former allocation (vaccine dose or placebo), so the placebo control carries over from the Phase I allocation; the registry does not list this record as randomized. Control is Al(OH)3 adjuvant alone. Recombinant TSST-1 toxoid variant against staphylococcal toxic shock. AE time frame not given."
},
{
"nct": "NCT02978222",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Folate receptor alpha peptide cancer vaccine in ovarian cancer; control GM-CSF alone."
},
{
"nct": "NCT02992197",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"rotavirus"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Single vs double Rotarix inoculum; both arms get Rotarix."
},
{
"nct": "NCT02998996",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"other"
],
"adjuvant": "other"
},
{
"id": "EG001",
"platforms": [
"other"
],
"adjuvant": "other"
},
{
"id": "EG002",
"platforms": [
"other"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Intranasal HA antigen with 1% or 2% Endocine or alone vs intranasal saline. EG004 (i.m. comparator) and EG005 (i.n. comparator) left out: active comparators on a different schedule. Platform 'other': 15 ug HA/strain influenza antigen, record does not say split (inactivated) or subunit (protein)."
},
{
"nct": "NCT03008122",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"inactivated"
],
"adjuvant": "aluminium"
},
{
"id": "EG001",
"platforms": [
"inactivated"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"zika"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "ZPIV with aluminium hydroxide; placebo composition not given. Flavivirus-endemic area, healthy adults."
},
{
"nct": "NCT03012100",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Folate receptor alpha peptide cancer vaccine in triple negative breast cancer."
},
{
"nct": "NCT03014089",
"eligible": false,
"exclusion_reason": "other",
"comparisons": [],
"targets": [
"zika"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "AE group titles and descriptions conflict on which group got placebo: titles put placebo at EG003, descriptions at EG001 (EG001 'mRNA-1325 25 mcg' described as placebo, EG003 'Placebo' described as 100 mcg). The placebo group cannot be identified from the record."
},
{
"nct": "NCT03014622",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "DaxibotulinumtoxinA for glabellar lines; no vaccine."
},
{
"nct": "NCT03014635",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "DaxibotulinumtoxinA for glabellar lines; no vaccine."
},
{
"nct": "NCT03018288",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "HSPPC-96 autologous tumor vaccine in glioblastoma."
},
{
"nct": "NCT03031912",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG006",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG008",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001",
"EG003",
"EG005",
"EG007",
"EG009"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"ebola"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "V920 (rVSV-ZEBOV) in HIV-infected adults and adolescents; CD4 cohorts pooled. Placebo normal saline."
},
{
"nct": "NCT03040687",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [
"shigella_etec"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Oral bovine serum immunoglobulin (passive antibody) against ETEC challenge; no vaccine."
},
{
"nct": "NCT03051516",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [
"hpv"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Gardasil 9 given as therapy to interrupt progression of existing high-grade vulvar or anal lesions (HPV-lesion use)."
},
{
"nct": "NCT03055000",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"other"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Target 'other': mosquito-borne diseases in general (AGS-v, mosquito saliva peptides). Adjuvanted arm uses Montanide ISA-51. Placebo water for injection."
},
{
"nct": "NCT03058692",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "seasonal quadrivalent influenza vaccine on Day 172"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "M-001 recombinant epitope protein, adjuvant not stated. Both arms get IIV4 on Day 172; placebo saline."
},
{
"nct": "NCT03060629",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector",
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"hiv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Ad26.Mos4.HIV plus aluminium phosphate-adjuvanted clade C gp140; 'matching placebo' composition not given."
},
{
"nct": "NCT03073525",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Vigil autologous tumor cell immunotherapy with atezolizumab in gynecological cancers."
},
{
"nct": "NCT03090191",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"c_difficile"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Toxoid-based C. difficile vaccine, adjuvant not stated; placebo normal saline."
},
{
"nct": "NCT03092791",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"inactivated"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"polio"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Only the adult lead-in cohort is placebo-controlled (EG000 vs EG001). Toddler and infant cohorts (EG002-EG007) left out: control is reference IPV. sIPV adjuvant not stated."
},
{
"nct": "NCT03095599",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"inactivated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "IVACFLU-S split TIV, composition given without adjuvant; placebo PBS."
},
{
"nct": "NCT03101111",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"chikungunya"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Control arm received MMR vaccine (active control); saline was only a dummy injection in both arms."
},
{
"nct": "NCT03101267",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "ASP4070, an allergy vaccine for cedar pollinosis."
},
{
"nct": "NCT03102034",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Intranasal live attenuated RSV in seronegative infants; placebo isotonic diluent."
},
{
"nct": "NCT03110770",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG003",
"platforms": [
"dna"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG004"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"zika"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Only Part B was randomized against placebo (Group 4 vs Group 5); Part A groups EG000-EG002 left out (no placebo in Part A). Placebo PBS."
},
{
"nct": "NCT03122223",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector",
"protein"
],
"adjuvant": "other"
},
{
"id": "EG001",
"platforms": [
"viral_vector",
"protein"
],
"adjuvant": "other"
},
{
"id": "EG002",
"platforms": [
"viral_vector",
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"hiv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "ALVAC-HIV plus gp120 with MF59 (EG000) or AS01B (EG001, EG002) vs sodium chloride."
},
{
"nct": "NCT03135834",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"meningococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "MenABCWY vs licensed rLP2086 + MenACWY-CRM (active control); saline only balances injections."
},
{
"nct": "NCT03143218",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"malaria"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "RTS,S/AS01 has no placebo: the SMC-alone arm received rabies and hepatitis A vaccines as control vaccines; placebo was given only for SMC drugs."
},
{
"nct": "NCT03146403",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [
"herpes_simplex"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "GEN-003 therapeutic HSV-2 vaccine (maintenance dose) in people with genital herpes."
},
{
"nct": "NCT03158038",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Monovalent cold-adapted LAIV intranasal; matching placebo composition not given."
},
{
"nct": "NCT03170609",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"other"
],
"adjuvant": "aluminium"
},
{
"id": "EG001",
"platforms": [
"other"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"other"
],
"adjuvant": "aluminium"
},
{
"id": "EG003",
"platforms": [
"other"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"other"
],
"adjuvant": "aluminium"
},
{
"id": "EG005",
"platforms": [
"other"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG006"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"group_b_strep"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Platform 'other': record calls GBS6 only a multivalent GBS vaccine (believed a capsular polysaccharide-CRM197 conjugate, which would be polysaccharide). Adjuvant per group: with or without aluminium phosphate. Placebo saline."
},
{
"nct": "NCT03172975",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "controlled human hookworm infection on Day 140, albendazole at end"
}
],
"targets": [
"other"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Target 'other': hookworm (Necator americanus). EG001/EG002 add CpG 10104 or GLA-AF as co-administered adjuvants (TLR agonists), treated as vaccine formulations, all with Alhydrogel. Placebo saline."
},
{
"nct": "NCT03180801",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"other"
],
"adjuvant": "other"
},
{
"id": "EG002",
"platforms": [
"other"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "adjuvant",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "AEs counted only until the influenza challenge. Placebo is Montanide ISA-51 emulsion. Platform 'other': record does not say what FLU-v is (believed synthetic peptides, which would be protein)."
},
{
"nct": "NCT03181789",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"dna"
],
"adjuvant": "other"
},
{
"id": "EG001",
"platforms": [
"dna"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG002",
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "electroporation delivery in both arms"
}
],
"targets": [
"hiv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "HIV gag pDNA vaccines with IL-12 pDNA, which the record calls the adjuvant, coded as adjuvant 'other' rather than a separate immune modulator. Both control groups saline by electroporation."
},
{
"nct": "NCT03201211",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"other"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Long-term follow-up (Month 20 to 50, SAEs only, no vaccine given) of the parent study's randomized arms: AS01E-adjuvanted NTHi-Mcat protein vaccine (two formulations, pooled) vs saline; no crossover reported. Target other: non-typeable Haemophilus influenzae and Moraxella catarrhalis."
},
{
"nct": "NCT03220737",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001",
"EG003",
"EG005"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"cholera"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Vaxchora (CVD 103-HgR) in children; age cohorts pooled; placebo saline. Historical adult control has no AE group. AE groups are the safety population as treated."
},
{
"nct": "NCT03227029",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Two intranasal live attenuated RSV candidates vs isotonic diluent."
},
{
"nct": "NCT03275389",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Control arm is Fluarix Quadrivalent (active); placebo only fills a Day 57 dose slot, and AE groups are not split by dose."
},
{
"nct": "NCT03281876",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"other"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Target 'other': non-typeable H. influenzae and Moraxella catarrhalis (COPD exacerbations). Record says the vaccine is adjuvanted but not with what. COPD patients (arm text says 'healthy', title says COPD)."
},
{
"nct": "NCT03284710",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"hiv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "All four arms get ALVAC-HIV plus gp120 (MF59, alum, or none, different schedules); no placebo group."
},
{
"nct": "NCT03284866",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [
"hpv"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Gardasil 9 given as 'HPV vaccine therapy' to reduce high-grade cervical lesions in HIV-infected women with HPV in a test-and-treat program (HPV-lesion use)."
},
{
"nct": "NCT03293498",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "NanoFlu vs Fluzone HD on Day 0 (active control); saline only fills Day 21 in the control arm."
},
{
"nct": "NCT03295318",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"meningococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "NmCV-5 formulations vs Menactra (active control)."
},
{
"nct": "NCT03300050",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated",
"inactivated"
],
"adjuvant": "other"
},
{
"id": "EG001",
"platforms": [
"live_attenuated",
"inactivated"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"inactivated"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG002",
"EG004"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Two schedules (intranasal LAIV then IM IIV; IM IIV twice) each with a route-matched saline/PBS placebo, pooled as one design. AS03 is in the second dose of EG000 and both doses of EG003."
},
{
"nct": "NCT03301051",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Plant-derived quadrivalent VLP; adjuvant not stated. EG000's description says 'vaccine or placebo', read as a template slip given its title."
},
{
"nct": "NCT03303625",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001",
"EG003"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Ad26.RSV.preF; adult and toddler cohorts pooled."
},
{
"nct": "NCT03312231",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "H7N9 doses with or without AS03; no placebo arm."
},
{
"nct": "NCT03313037",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"pneumococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "20vPnC then saline vs 13vPnC then PPSV23 (active control)."
},
{
"nct": "NCT03318315",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Open-label; the IIV4-only group got no placebo in place of the H7N9 vaccine."
},
{
"nct": "NCT03325075",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG008",
"platforms": [
"other"
],
"adjuvant": "unknown"
},
{
"id": "EG009",
"platforms": [
"other"
],
"adjuvant": "unknown"
},
{
"id": "EG010",
"platforms": [
"other"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG011"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"chikungunya"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "AE groups report the same people by period: Part A after vaccination 1 (EG000/002/004 vs EG006), after vaccination 2 (EG001/003/005 vs EG007), and Part B long-term follow-up (EG008-010 vs EG011). Took Part B, the longest placebo-controlled follow-up; the vaccination-1 set is the alternative if all participants are needed. Platform 'other': record does not name it (VAL-181388 believed an mRNA vaccine)."
},
{
"nct": "NCT03334695",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Took the post-dose groups (EG000/EG001); left out the post-challenge groups (EG002/EG003), the same participants after an RSV challenge given to all."
},
{
"nct": "NCT03339713",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "seasonal influenza vaccine (Fluarix)"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Planned crossover: took the post-dose 1 groups (Ad26.RSV.preF + Fluarix vs placebo + Fluarix); left out post-dose 2 groups after crossover."
},
{
"nct": "NCT03341637",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"dengue"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": ""
},
{
"nct": "NCT03342898",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"dengue",
"yellow_fever"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Every arm gets TDV and YF-17D in different sequences; groups cover the whole study, placebo only fills a slot."
},
{
"nct": "NCT03343626",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"inactivated"
],
"adjuvant": "aluminium"
},
{
"id": "EG002",
"platforms": [
"inactivated"
],
"adjuvant": "aluminium"
},
{
"id": "EG003",
"platforms": [
"inactivated"
],
"adjuvant": "aluminium"
},
{
"id": "EG005",
"platforms": [
"inactivated"
],
"adjuvant": "aluminium"
},
{
"id": "EG006",
"platforms": [
"inactivated"
],
"adjuvant": "aluminium"
},
{
"id": "EG007",
"platforms": [
"inactivated"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG000",
"EG004"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"zika"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Flavivirus-naive and -primed cohorts pooled."
},
{
"nct": "NCT03376477",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"polysaccharide"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "inert",
"offspring": false,
"background": "lenalidomide and GM-CSF myeloma cell vaccine"
}
],
"targets": [
"pneumococcal"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Prevnar13 vs saline placebo Prevnar, both arms on lenalidomide + GVAX (Arm A vs Arm B). Arm C (EG001) left out: it also lacks GVAX, so differs by more than the vaccine."
},
{
"nct": "NCT03382418",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"hiv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": ""
},
{
"nct": "NCT03387137",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001",
"EG003"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Seropositive and seronegative cohorts pooled; placebo nose drops of unstated composition."
},
{
"nct": "NCT03408262",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG005",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG006",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG007",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "CN54gp140/MPLA protein vaccine"
}
],
"targets": [
"hiv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Every group gets CN54gp140/MPLA; Group A (oral and IM placebo) is placebo for Ad4-EnvCN54 and/or MVA-CN54 given to the other groups (E: MVA only; B-D: Ad4; F-H: both)."
},
{
"nct": "NCT03409276",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG003",
"platforms": [
"dna",
"protein"
],
"adjuvant": "other"
},
{
"id": "EG004",
"platforms": [
"dna",
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG000",
"EG002"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"hiv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Part A (protein/GLA-SE) and Part B (DNA and protein/GLA-SE) pooled, each with its own saline placebo; GLA-SE is a non-aluminium adjuvant."
},
{
"nct": "NCT03423173",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"dengue"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Three TDV lots pooled."
},
{
"nct": "NCT03443427",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"other"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Both arms get three doses of the NTHi-Mcat vaccine on different schedules; placebo only fills the fourth slot. Target other: non-typeable H. influenzae and Moraxella catarrhalis."
},
{
"nct": "NCT03450915",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "M-001 recombinant multi-epitope protein; record states no adjuvant either way."
},
{
"nct": "NCT03461276",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "ABvac40 is an anti-amyloid vaccine for Alzheimer's disease."
},
{
"nct": "NCT03483116",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"rotavirus"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "All arms get three RV3-BB doses (neonatal or infant schedule) with placebo in the remaining slot; it compares doses and schedules."
},
{
"nct": "NCT03483961",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"chikungunya"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "All ten groups get CHIKV VLP (doses, adjuvant, schedules); placebo only fills slots."
},
{
"nct": "NCT03486834",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"other"
],
"adjuvant": "aluminium"
},
{
"id": "EG001",
"platforms": [
"other"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"cmv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "3-dose and 2-dose V160 pooled. Platform other: V160 is a whole-virus CMV vaccine (replication-defective), not clearly live attenuated or inactivated from the record; adjuvant MAPA (aluminium phosphate)."
},
{
"nct": "NCT03491553",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Selgantolimod is an oral TLR8 agonist for chronic hepatitis B, not a vaccine."
},
{
"nct": "NCT03500679",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"polysaccharide"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"e_coli"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "ExPEC4V O-antigen conjugate; adjuvant not stated."
},
{
"nct": "NCT03503058",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"other"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
},
{
"vaccine_groups": [
{
"id": "EG002",
"platforms": [
"other"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "chloroquine chemoprophylaxis"
}
],
"targets": [
"malaria"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Two comparisons: PfSPZ Vaccine vs saline; PfSPZ-CVac vs saline, both with weekly chloroquine. Platform other: radiation-attenuated (non-replicating) whole sporozoites, and infectious sporozoites under chloroquine."
},
{
"nct": "NCT03510481",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"other"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"other"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG002",
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "artemether-lumefantrine before doses 3 and 4"
}
],
"targets": [
"malaria"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Two dosing schedules pooled, each with its saline control. Platform other: radiation-attenuated (non-replicating) whole sporozoites."
},
{
"nct": "NCT03512249",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"tuberculosis"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Given to prevent TB recurrence in adults successfully treated for pulmonary TB, taken as preventive; IC31 (KLK + ODN1a) is a non-aluminium adjuvant."
},
{
"nct": "NCT03518125",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"anthrax"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "BioThrax vs AV7909 regimens; saline only fills a skipped dose."
},
{
"nct": "NCT03520959",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "CMB305 is a NY-ESO-1 cancer vaccine for synovial sarcoma."
},
{
"nct": "NCT03525119",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG002",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "inert",
"offspring": false,
"background": "hepatitis A vaccine on Day 1"
}
],
"targets": [
"dengue"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "TDV+HAV/TDV vs HAV+placebo/placebo. EG001 (TDV + HAV placebo) left out: no placebo group without HAV vaccine; its contrast with EG000 is an active control."
},
{
"nct": "NCT03527173",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"other"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "oral S. sonnei 53G challenge at Day 57"
}
],
"targets": [
"shigella_etec"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Whole-arm groups, vaccination and challenge periods together. Platform other: GVGH 1790GAHB is a GMMA (outer membrane vesicle) vaccine; adjuvant not stated in the record."
},
{
"nct": "NCT03529773",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG010",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG011",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG012",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG005",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG006",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG007",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG008",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG009",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG003",
"EG013"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
},
{
"vaccine_groups": [
{
"id": "EG021",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG023",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG025",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG027",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG029",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG031",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG022",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG024",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG026",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG028",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG030",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG032",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG020",
"EG039"
],
"placebo_content": "inert",
"offspring": false,
"background": "seasonal inactivated influenza vaccine at Day 35"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Sentinel cohort (RSV vaccine with or without Al(OH)3 vs placebo) and expanded cohort (RSV vaccine + placebo then SIIV vs placebo + placebo then SIIV) as two comparisons, ages pooled. Left out the expanded groups given SIIV with the RSV vaccine on Day 1 (EG014-EG019, EG033-EG038): no placebo group got SIIV on Day 1. EG028 taken by its title (its description repeats the SIIV-on-Day-1 schedule). Placebo described as saline control."
},
{
"nct": "NCT03541499",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"tetanus_diphtheria_pertussis"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "BPZE1 doses by VaxINator vs placebo by VaxINator. Left out EG002 (BPZE1 by syringe, n=5): its delivery differs from the placebo's. Target is pertussis."
},
{
"nct": "NCT03548064",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG006",
"platforms": [
"protein"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG002",
"EG005",
"EG007"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"shigella_etec"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "dmLT (detoxified ETEC heat-labile toxin) given as the ETEC antigen; oral, sublingual and intradermal routes pooled, each with its own placebo; no separate adjuvant."
},
{
"nct": "NCT03553940",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "licensed quadrivalent inactivated influenza vaccine at Day 92"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "M2SR is a single-replication (M2-deficient) influenza virus the record calls live attenuated."
},
{
"nct": "NCT03560258",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Therapeutic HIV DNA vaccine in people with HIV on antiretroviral therapy."
},
{
"nct": "NCT03562377",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [
"tetanus_diphtheria_pertussis",
"meningococcal"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Tests tralokinumab's effect on responses to Tdap and meningococcal vaccines that every arm receives."
},
{
"nct": "NCT03564444",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": ""
},
{
"nct": "NCT03572062",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG003",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG004",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG005",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG006",
"platforms": [
"protein"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG007"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "seasonal inactivated influenza vaccine"
},
{
"vaccine_groups": [
{
"id": "EG008",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG009"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Primary cohort (RSVpreF with Al(OH)3, CpG/Al(OH)3 or none, all with SIIV) vs placebo + SIIV; month-0/month-2 cohort (CpG/Al(OH)3, no SIIV) vs placebo as a second comparison. CpG/Al(OH)3 counted as aluminium."
},
{
"nct": "NCT03576183",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"other"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "oral ETEC challenge strain"
}
],
"targets": [
"cholera",
"shigella_etec"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Whole-arm groups including the ETEC challenge both arms got. Platform other: VLA1701 is an investigational oral cholera/ETEC vaccine whose composition the record doesn't give; placebo is its buffer."
},
{
"nct": "NCT03579459",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"c_difficile"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Toxoid vaccine, lots pooled in the tables; adjuvant not stated."
},
{
"nct": "NCT03583606",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG002",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "inert",
"offspring": false,
"background": "ChAd3-EBO-Z prime on Day 1"
}
],
"targets": [
"ebola"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Every arm gets ChAd3-EBO-Z on Day 1; took MVA-BN-Filo vs saline on Day 8 (EG002 vs EG000). Left out EG001 (a second ChAd3-EBO-Z dose vs placebo is a dose comparison of the same vaccine)."
},
{
"nct": "NCT03589807",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "All arms get H7N9 vaccine; compares strains, intervals and adjuvant."
},
{
"nct": "NCT03596801",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG002",
"EG005"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Two live-attenuated RSV candidates in seropositive and seronegative cohorts pooled; placebo nose drops of unstated composition."
},
{
"nct": "NCT03606213",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Therapeutic HIV DNA vaccine with IL-12 plasmid in people with HIV on ART."
},
{
"nct": "NCT03606512",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG002",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Ad26.RSV.preF vs saline placebo. Left out EG001 (placebo-arm toddlers given Nimenrix on Day 57, an active vaccine the vaccine arm didn't get)."
},
{
"nct": "NCT03610581",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Therapeutic Ad26/MVA HPV vaccine for women with existing cervical HPV16/18 infection."
},
{
"nct": "NCT03611946",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001",
"EG003"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"zika"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Chimeric live-attenuated Zika (on DEN4delta30); two dose cohorts pooled."
},
{
"nct": "NCT03615482",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"pneumococcal",
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Both arms get V114 and QIV, together or 30 days apart; groups cover the whole study."
},
{
"nct": "NCT03621670",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "routine infant vaccines (PCV13/PCV20, Pediarix, Hiberix, Rotarix, MMR, varicella)"
}
],
"targets": [
"meningococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": ""
},
{
"nct": "NCT03629080",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "kidney transplant with pre-emptive CMV management"
},
{
"vaccine_groups": [
{
"id": "EG002",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "kidney transplant with 3-6 months antiviral prophylaxis"
}
],
"targets": [
"cmv"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Pre-emptive and prophylactic management strata kept as separate comparisons (background care differs). Left out EG004/EG005, CMV-seropositive patients given HB-101 with no placebo. HB-101 is replication-deficient rLCMV vectors."
},
{
"nct": "NCT03629886",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"hpv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Follow-up of HPV-039: women vaccinated before get nothing now; former placebo recipients get the vaccine. No placebo given in this study, and the groups were set by the earlier trial."
},
{
"nct": "NCT03635086",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"chikungunya"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "All groups get MV-CHIK (formulations, doses, one or two doses)."
},
{
"nct": "NCT03636906",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "The control group gets licensed meningococcal or pneumococcal vaccines on Day 1 in place of the first ChAd155-RSV dose (placebo only in the later slots); the RSV groups get the same comparators later, so the control is active for the RSV dose window."
},
{
"nct": "NCT03658629",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Every arm gets an influenza vaccine (Quad-NIV formulations or licensed comparators); placebo only fills Day 28."
},
{
"nct": "NCT03674177",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Unadjuvanted RSV maternal vaccine (by its title) given to non-pregnant women; three doses pooled."
},
{
"nct": "NCT03676764",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Mass or targeted azithromycin vs placebo; no vaccine is tested."
},
{
"nct": "NCT03682107",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"dna"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"dna"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"dna"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"dna"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG004"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"other"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Target other: Andes hantavirus (hantavirus pulmonary syndrome). Doses and 3- or 4-dose regimens pooled against pooled saline placebo; vaccine groups include one open-label sentinel each."
},
{
"nct": "NCT03682120",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "All arms get H7N9 vaccine (doses, with or without MF59); no placebo arm."
},
{
"nct": "NCT03707041",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "P218 is an antimalarial drug tested against PfSPZ Challenge; no vaccine is tested."
},
{
"nct": "NCT03718130",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG004",
"platforms": [
"dna"
],
"adjuvant": "none"
},
{
"id": "EG005",
"platforms": [
"dna"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG000",
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "HTNV DNA vaccine by electroporation (same dose and route)"
}
],
"targets": [
"other"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Target 'other': hantaviruses (Hantaan and Puumala). No placebo arm as such, but groups 1-2 got HTNV DNA + 0.9% saline in place of the PUUV DNA that groups 5-6 got with the same HTNV dose, route and device, so PUUV DNA vs saline on an HTNV background. ID and IM cohorts pooled. Groups 3-4 (PUUV + saline) left out because groups 5-6 can be used once; pairing them instead would test HTNV on a PUUV background. Open label."
},
{
"nct": "NCT03738241",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "All groups get 2017 H7N9 vaccine with or without AS03; no placebo."
},
{
"nct": "NCT03760146",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"pneumococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "20vPnC compared with 13vPnC (and 13vPnC/PPSV23); saline only fills the second slot in cohort 1."
},
{
"nct": "NCT03765073",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"polysaccharide"
],
"adjuvant": "aluminium"
},
{
"id": "EG006",
"platforms": [
"polysaccharide"
],
"adjuvant": "aluminium"
},
{
"id": "EG008",
"platforms": [
"polysaccharide"
],
"adjuvant": "aluminium"
},
{
"id": "EG010",
"platforms": [
"polysaccharide"
],
"adjuvant": "aluminium"
},
{
"id": "EG001",
"platforms": [
"polysaccharide"
],
"adjuvant": "none"
},
{
"id": "EG007",
"platforms": [
"polysaccharide"
],
"adjuvant": "none"
},
{
"id": "EG009",
"platforms": [
"polysaccharide"
],
"adjuvant": "none"
},
{
"id": "EG011",
"platforms": [
"polysaccharide"
],
"adjuvant": "none"
},
{
"id": "EG020",
"platforms": [
"polysaccharide"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG002",
"EG012",
"EG021"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
},
{
"vaccine_groups": [
{
"id": "EG013",
"platforms": [
"polysaccharide"
],
"adjuvant": "aluminium"
},
{
"id": "EG015",
"platforms": [
"polysaccharide"
],
"adjuvant": "aluminium"
},
{
"id": "EG017",
"platforms": [
"polysaccharide"
],
"adjuvant": "aluminium"
},
{
"id": "EG014",
"platforms": [
"polysaccharide"
],
"adjuvant": "none"
},
{
"id": "EG016",
"platforms": [
"polysaccharide"
],
"adjuvant": "none"
},
{
"id": "EG018",
"platforms": [
"polysaccharide"
],
"adjuvant": "none"
},
{
"id": "EG022",
"platforms": [
"polysaccharide"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG019",
"EG023"
],
"placebo_content": "inert",
"offspring": true,
"background": "none"
}
],
"targets": [
"group_b_strep"
],
"off_target": false,
"pregnant": true,
"patients": false,
"note": "Women: Stage 1 nonpregnant and Stage 2-3 pregnant groups pooled (same design, saline control); infants of Stage 2-3 mothers as the offspring comparison. Left out Stage 1 booster groups EG003-EG005 (same participants, all boosted with GBS6, no placebo). GBS6 taken as a multivalent capsular polysaccharide (conjugate) vaccine; adjuvant by group, with or without AlPO4."
},
{
"nct": "NCT03769194",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"lyme"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": ""
},
{
"nct": "NCT03807245",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "adjuvant",
"offspring": false,
"background": "none"
}
],
"targets": [
"group_b_strep"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Placebo is buffer with Alhydrogel."
},
{
"nct": "NCT03807843",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"chikungunya"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "V184 is a live measles (Schwarz) vector expressing chikungunya structural proteins, coded viral_vector."
},
{
"nct": "NCT03814590",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG005",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG006",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG007",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG008",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG009",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG010",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG011",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG012",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG003",
"EG013"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Part A (18-40) and Part B (60-80) pooled, each with its own saline placebo. Plain groups unadjuvanted; AS01E/AS01B groups adjuvant other."
},
{
"nct": "NCT03819049",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG005",
"platforms": [
"polysaccharide"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG006"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"e_coli"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Only Cohort 2 has a placebo; Cohort 1 groups (ExPEC10V doses, ExPEC4V, Prevnar 13 active control) left out. ExPEC10V is an O-antigen conjugate; adjuvant not stated. Cohort 2 required a history of UTI but enrolled adults in stable health, so patients false."
},
{
"nct": "NCT03821272",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [
"hpv"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "PepCan (HPV16 E6 peptides with Candin) given to head and neck cancer patients in remission to reduce recurrence: a cancer/therapeutic vaccine."
},
{
"nct": "NCT03827395",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"hepatitis_e"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "HEV 239 recombinant capsid protein on aluminium hydroxide; placebo normal saline."
},
{
"nct": "NCT03840174",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"other"
],
"adjuvant": "aluminium"
},
{
"id": "EG001",
"platforms": [
"other"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG002",
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"cmv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Seronegative and seropositive subgroups pooled. Platform other: V160 is a CMV vaccine whose platform the record does not describe (a whole-virus, replication-defective product); aluminium phosphate adjuvant stated."
},
{
"nct": "NCT03844386",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [
"hiv"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Therapeutic MVA HIV vaccines in HIV-infected adults on ART."
},
{
"nct": "NCT03866187",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [
"hepatitis_b"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Therapeutic HBV vaccine regimen in chronic hepatitis B patients."
},
{
"nct": "NCT03869333",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "unknown"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "unknown"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"shigella_etec"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Invaplex AR-DETOX, a purified S. flexneri 2a invasin protein complex (with detoxified LPS), coded protein; adjuvant not stated."
},
{
"nct": "NCT03880474",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "MVA vector carrying influenza NP+M1."
},
{
"nct": "NCT03883113",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Same participants reported by vaccination phase (EG000/EG001) and H3N2 challenge phase (EG002/EG003); took the vaccination-phase groups, which hold every vaccinated participant before the challenge virus that both arms got. Challenge-phase groups left out."
},
{
"nct": "NCT03916185",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Three live-attenuated intranasal RSV candidates against one placebo (nose drops, composition not given)."
},
{
"nct": "NCT03917654",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"malaria"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Pfs230D1M-EPA/AS01 compared with active control vaccines (Havrix, Typhim Vi, Menactra) and no-intervention arms; no placebo."
},
{
"nct": "NCT03918629",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"c_difficile"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "2-dose versus 3-dose C. difficile toxoid vaccine; placebo only replaces one dose in the 2-dose arm."
},
{
"nct": "NCT03926728",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG003",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG004",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG005",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG006",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG007",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG008",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG009",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG010",
"EG011"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"other"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Target other: Chlamydia trachomatis (trachoma/genital chlamydia). CTH522 recombinant protein with CAF01 or CAF09b (liposomal adjuvants); some groups also got unadjuvanted CTH522 topical-ocular or intradermal boosts. Cohort F (F1, F2) saline placebo."
},
{
"nct": "NCT03934541",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG002",
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"hiv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "MPER-656 peptide liposomes with aluminium hydroxide, in HIV-uninfected adults; two dose groups each with its own saline placebo, pooled."
},
{
"nct": "NCT03942406",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG002",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "Boostrix (Tdap) IM prime with intranasal placebo on Day 1"
}
],
"targets": [
"tetanus_diphtheria_pertussis"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Only clean pair: Boostrix-primed participants randomized to BPZE1 vs intranasal placebo boost at Day 85. BPZE1-primed groups (EG000, EG001) left out: both arms got BPZE1 at prime, and prime BPZE1 vs Boostrix is an active control. Lead-in 10^7 groups (EG004-EG006) left out: their cohort had no placebo-boost group."
},
{
"nct": "NCT03952650",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"other"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG005"
],
"placebo_content": "inert",
"offspring": false,
"background": "pyrimethamine 75 mg on day 0 after each injection; artemether/lumefantrine clearance"
},
{
"vaccine_groups": [
{
"id": "EG003",
"platforms": [
"other"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG006"
],
"placebo_content": "inert",
"offspring": false,
"background": "pyrimethamine 75 mg on days 2 and 3 after each injection; artemether/lumefantrine clearance"
}
],
"targets": [
"malaria"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "PfSPZ-CVac: platform other, fully infectious non-attenuated PfSPZ given under antimalarial drug cover. Main-phase groups only, split by the pyrimethamine schedule both sides shared. Single-dose pilot groups (EG000, EG002, EG004) had no placebo group; no chloroquine placebo group was reported."
},
{
"nct": "NCT03961555",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [
"rabies"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Tests SYN023 monoclonal antibodies against human rabies immune globulin; every arm got rabies vaccine. Enrolled after WHO category 3 rabies exposure."
},
{
"nct": "NCT03964415",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector",
"protein"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"hiv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Ad26.Mos4.HIV plus clade C and mosaic gp140 protein; the protein is called adjuvanted but the record (truncated) does not name the adjuvant. Healthy MSM and transgender people."
},
{
"nct": "NCT03969212",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Baloxavir marboxil (antiviral drug) given to influenza-infected index patients."
},
{
"nct": "NCT03970733",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"lyme"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Main study phase groups taken (first randomization). Booster-phase groups EG003/EG004 are a later re-randomization of higher-dose recipients and are left out."
},
{
"nct": "NCT03982199",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector",
"protein"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Main cohort groups taken (placebo-controlled until each subcohort's revaccination). Revaccination subcohort groups EG002-EG013 left out: placebo recipients crossed over to vaccine and none has placebo. Adjuvant of the preF protein component not stated."
},
{
"nct": "NCT03989102",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"other"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"other"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "inert",
"offspring": false,
"background": "artemether/lumefantrine before 1st and 3rd injections"
}
],
"targets": [
"malaria"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Platform other: radiation-attenuated, non-replicating P. falciparum sporozoites (PfSPZ Vaccine). Women of childbearing potential, not pregnant."
},
{
"nct": "NCT03999554",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"other"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"other"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"other"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"other"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG004"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Platform other: M2SR, an M2-deficient single-replication influenza virus given intranasally (platform not described in the record). Sing2016 and Bris10 M2SR groups all against one saline placebo; Bris10 is a second vaccine, not a control."
},
{
"nct": "NCT03999996",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG002",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "TDV primary vaccination in parent trials"
}
],
"targets": [
"dengue"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Booster-phase groups taken: the parent trials' first randomization has no groups here, and the prior-to-booster groups are TDV recipients only."
},
{
"nct": "NCT04009824",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG003",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG004",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"other"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Target other: mosquito-borne diseases; AGS-v PLUS is a synthetic mosquito salivary peptide vaccine. Adjuvants: none, Montanide ISA-51, Alhydrogel."
},
{
"nct": "NCT04019444",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"rabies"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "ChAd155-RG compared with RabAvert active control; placebo only fills dosing visits."
},
{
"nct": "NCT04026009",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG001",
"EG004"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"c_difficile"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "18-45 and 50-70 cohorts pooled. A subcohort of the 50-70 vaccine groups got a third dose at about Month 17 with no placebo counterpart; it is not reported separately, so the groups are kept."
},
{
"nct": "NCT04032093",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG003",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG004"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
},
{
"vaccine_groups": [
{
"id": "EG005",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG007",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG006",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG008",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG009"
],
"placebo_content": "inert",
"offspring": true,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": true,
"patients": false,
"note": "Maternal groups and infant groups as separate comparisons; infants described by their mothers' vaccine."
},
{
"nct": "NCT04033068",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"zika"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "MV-ZIKA-RSP (V187), a measles-vectored Zika vaccine."
},
{
"nct": "NCT04060277",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "letermovir prophylaxis days 7-100 after haploidentical HCT"
}
],
"targets": [
"cmv"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Triplex (MVA carrying CMV antigens) given after transplant to prevent CMV infection, taken as preventive."
},
{
"nct": "NCT04064905",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"mrna"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"zika"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": ""
},
{
"nct": "NCT04071158",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG004"
],
"placebo_content": "inert",
"offspring": false,
"background": "Tdap"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Placebo group got Tdap, so only RSV+Tdap groups compare. RSV+placebo groups (EG000, EG002) left out: no placebo group without Tdap. Non-pregnant women."
},
{
"nct": "NCT04075318",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "UB-312 is an alpha-synuclein peptide vaccine for Parkinson's disease, a non-infectious target; Part B enrolled Parkinson's patients."
},
{
"nct": "NCT04078022",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"polysaccharide"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"shigella_etec"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Took the Vaccine/Placebo Enrolled groups (all randomized, vaccination period); Challenged groups EG002/EG003 report subsets of the same participants after S. flexneri challenge and are left out. SF2a-TT15 is a synthetic carbohydrate-tetanus toxoid conjugate; adjuvant not stated."
},
{
"nct": "NCT04086472",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Clesrovimab is a monoclonal antibody, tested in an RSV challenge model."
},
{
"nct": "NCT04090658",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "RSVPreF3 with AS01B."
},
{
"nct": "NCT04091451",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"zoster"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Shingrix (gE/AS01B) to prevent recurrence in adults with a prior zoster episode; prior episode taken as history, not a current condition, so patients false."
},
{
"nct": "NCT04126213",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
},
{
"vaccine_groups": [
{
"id": "EG003",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"protein"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG005"
],
"placebo_content": "inert",
"offspring": true,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": true,
"patients": false,
"note": "Unadjuvanted RSVPreF3 maternal vaccine; mothers and their infants as separate comparisons."
},
{
"nct": "NCT04138056",
"eligible": false,
"exclusion_reason": "other",
"comparisons": [],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "AE groups run through the extension, in which every group, including placebo+dTpa (EG004), got a second-stage RSVPreF3 dose; no group covers only the placebo-controlled period. Non-pregnant women."
},
{
"nct": "NCT04152161",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"tuberculosis"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "BCG revaccination of adolescents against TB (its own target)."
},
{
"nct": "NCT04176133",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Tests entolimod (TLR5 agonist drug) on response to high-dose influenza vaccine that every arm received."
},
{
"nct": "NCT04228783",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG003",
"EG005"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"ebola"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Lot-consistency groups and booster cohort (with its own placebo series) pooled: Ad26.ZEBOV and MVA-BN-Filo are both viral vectors."
},
{
"nct": "NCT04232280",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG005",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG006",
"platforms": [
"mrna"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG003",
"EG007"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"cmv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "CMV-seronegative and seropositive subgroups pooled."
},
{
"nct": "NCT04242264",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "oral S. sonnei 53G challenge on Day 57"
}
],
"targets": [
"shigella_etec"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "EG002 got one WRSs2 dose after a placebo dose; all groups challenged."
},
{
"nct": "NCT04250363",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [
"malaria"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "M5717 is an antimalarial drug tested in a PfSPZ challenge model; PfSPZ is the challenge agent, not a vaccine."
},
{
"nct": "NCT04305327",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Brodalumab and ustekinumab for psoriasis; no vaccine."
},
{
"nct": "NCT04318548",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"meningococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Every arm gets both MenB and MenACWY; placebo only staggers their timing."
},
{
"nct": "NCT04319380",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"malaria"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "RTS,S/AS01 compared with seasonal chemoprevention arm given Td control vaccine; no vaccine placebo."
},
{
"nct": "NCT04333732",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"covid19"
],
"off_target": true,
"pregnant": false,
"patients": false,
"note": "MMR (or MR) given to prevent COVID-19; both arms also got education and surveillance."
},
{
"nct": "NCT04348370",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"covid19"
],
"off_target": true,
"pregnant": false,
"patients": false,
"note": "BCG Tice given to health care workers to prevent COVID-19."
},
{
"nct": "NCT04349553",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"typhoid",
"other"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Target other: paratyphoid A (ZH9PA, live-attenuated S. Paratyphi A); ZH9 is live-attenuated S. Typhi. Placebo saline in bicarbonate buffer."
},
{
"nct": "NCT04355767",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Convalescent plasma for COVID-19 outpatients; no vaccine."
},
{
"nct": "NCT04365387",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [
"tetanus_diphtheria_pertussis",
"meningococcal"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Tests nemolizumab's effect on responses to Tdap and MCV4 that every arm received; atopic dermatitis patients."
},
{
"nct": "NCT04368728",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG005",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG006",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG010",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG013",
"platforms": [
"mrna"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG008",
"EG009",
"EG012"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Placebo-controlled follow-up groups for Phase 1 (BNT162b1 and BNT162b2), Phase 2/3 >=16 and Phase 3 12-15 pooled. Left out: open-label groups after placebo recipients crossed over (EG007, EG011, EG014); Phase 2 groups EG026/EG027, a subset of the Phase 2/3 >=16 participants; booster and BNT162b2SA groups (EG015-EG025), none with placebo."
},
{
"nct": "NCT04405076",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"mrna"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Part A groups only. Part B (open-label after unblinding, placebo recipients crossed over) and Part C (boosters, no placebo) left out."
},
{
"nct": "NCT04420221",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"other"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"other"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"other"
],
"adjuvant": "unknown"
},
{
"id": "EG003",
"platforms": [
"other"
],
"adjuvant": "unknown"
},
{
"id": "EG005",
"platforms": [
"other"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG004",
"EG006"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"s_aureus"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Dose-escalation epoch (healthy adults, pooled placebo) and proof-of-principle epoch (adults with a recent S. aureus SSTI) pooled. Platform other: Sa-5Ag, five S. aureus antigens not described further. Adjuvanted groups' adjuvant not named. patients true for the recent-SSTI epoch."
},
{
"nct": "NCT04424316",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
},
{
"vaccine_groups": [
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "not_stated",
"offspring": true,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": true,
"patients": false,
"note": "RSVpreF 120 mcg (Abrysvo, unadjuvanted); mothers and infants as separate comparisons."
},
{
"nct": "NCT04436276",
"eligible": false,
"exclusion_reason": "other",
"comparisons": [],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "AE groups run to Day 808 and, by their descriptions, include placebo recipients' Ad26.COV2.S dose after unblinding (and ad hoc boosters); no group covers only the placebo-controlled period."
},
{
"nct": "NCT04440163",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"meningococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "MenABCWY + saline compared with Trumenba + MenACWY-CRM, an active control; no placebo-only group."
},
{
"nct": "NCT04440176",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"meningococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Both groups get MenABCWY; they differ only in schedule (saline at month 12 in group 2)."
},
{
"nct": "NCT04445831",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Tau-targeted vaccines for early Alzheimer's disease."
},
{
"nct": "NCT04449276",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG005",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG006",
"platforms": [
"mrna"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG007"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "CVnCoV dose-escalation groups (2-20 ug) pooled against pooled placebo; placebo composition not given."
},
{
"nct": "NCT04453202",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector",
"protein"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"viral_vector",
"protein"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"viral_vector",
"protein"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"viral_vector",
"protein"
],
"adjuvant": "none"
},
{
"id": "EG005",
"platforms": [
"viral_vector",
"protein"
],
"adjuvant": "none"
},
{
"id": "EG006",
"platforms": [
"viral_vector",
"protein"
],
"adjuvant": "none"
},
{
"id": "EG008",
"platforms": [
"viral_vector",
"protein"
],
"adjuvant": "none"
},
{
"id": "EG009",
"platforms": [
"viral_vector",
"protein"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG004",
"EG007",
"EG010"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Ad26.RSV.preF plus RSV preF protein, all three cohorts pooled; adjuvant not stated, taken as none (Janssen's Ad26/preF protein combination is unadjuvanted). Placebo 'matching', composition not given."
},
{
"nct": "NCT04470427",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"mrna"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Took the Part A blinded groups; left out Part B open-label groups (incl. placebo crossovers) and the Part C booster."
},
{
"nct": "NCT04471038",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "SAB-176 is an anti-influenza immunoglobulin, not a vaccine."
},
{
"nct": "NCT04473690",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "KBP-COVID-19 (plant-made subunit) with CpG adjuvant, low and high dose pooled; placebo buffered saline."
},
{
"nct": "NCT04475081",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"covid19"
],
"off_target": true,
"pregnant": false,
"patients": false,
"note": "MMR-II given against COVID-19-associated sepsis (off-target); placebo sterile saline."
},
{
"nct": "NCT04491877",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG006",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG007",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001",
"EG003",
"EG005",
"EG008"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Intranasal live-attenuated RSVt, four cohorts and two formulations pooled; placebo composition not given."
},
{
"nct": "NCT04498247",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG004"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "V591 (measles-vectored). Took the post-vaccination-1 groups, which count every participant once; left out the post-vaccination-2 groups (EG005-EG007), a subset of the same people."
},
{
"nct": "NCT04502693",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"meningococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "MenABCWY lots compared with MenB and MenACWY schedules; placebo injections only keep the blind, no placebo-only group."
},
{
"nct": "NCT04505722",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Took the double-blind groups; left out the combined all-participants group (both arms) and the open-label booster groups."
},
{
"nct": "NCT04516746",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "AZD1222 vs saline, double-blind period."
},
{
"nct": "NCT04520659",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG004",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG005"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Took the combined Groups 1+2 (EG004, EG005); the per-group EG000-EG003 report the same participants. Placebo nose drops, composition not given."
},
{
"nct": "NCT04523571",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"mrna"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG002",
"EG005"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "BNT162b1 doses and both age cohorts pooled; placebo composition not given."
},
{
"nct": "NCT04523831",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Ivermectin plus doxycycline to treat COVID-19."
},
{
"nct": "NCT04526574",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"pneumococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Both groups get 20vPnC and SIIV, coadministered or a month apart; groups span both vaccinations, so no placebo-controlled group."
},
{
"nct": "NCT04535453",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG006",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG008",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG010",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG005",
"EG007",
"EG009",
"EG011"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Ad26.COV2.S doses, intervals, adults and adolescents pooled against the four placebo groups. Placebo recipients were later offered active vaccine (Amendment 5 / unblinding); no separate post-crossover groups are reported, so the placebo groups may include some post-crossover time."
},
{
"nct": "NCT04537208",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG003",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG005",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG006",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG007",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG008",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG009",
"platforms": [
"protein"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG004",
"EG010"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "CoV2 preS dTM with AF03 or AS03 (both non-aluminium), plus an unadjuvanted high-dose group; both cohorts pooled; placebo 0.9% saline."
},
{
"nct": "NCT04542330",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"covid19"
],
"off_target": true,
"pregnant": false,
"patients": false,
"note": "BCG-Denmark given to seniors for non-specific protection during the COVID-19 pandemic (off-target); placebo saline."
},
{
"nct": "NCT04544787",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG004",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG005",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG006"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"polio"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Placebo was randomized only in the IPV-primed stratum, so took its groups (two nOPV2 candidates vs placebo). Left out the OPV-primed groups EG000-EG003, which have no placebo. Placebo sugar syrup and propylene glycol."
},
{
"nct": "NCT04546724",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"chikungunya"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "VLA1553 vs PBS."
},
{
"nct": "NCT04556981",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"tuberculosis"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "M72/AS01E vs saline in virally suppressed people with HIV."
},
{
"nct": "NCT04568031",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "AZD1222 vs saline, cohorts C and D as reported."
},
{
"nct": "NCT04569786",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG004"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "V590 (rVSV-based) doses pooled across panels; placebo composition not given."
},
{
"nct": "NCT04588480",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"mrna"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Took the blinded groups; left out 'Placebo then BNT162b2' (post-crossover)."
},
{
"nct": "NCT04596878",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG002",
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"group_b_strep"
],
"off_target": false,
"pregnant": true,
"patients": true,
"note": "GBS-NN/NN2 on Alhydrogel vs saline in pregnant women with and without HIV, strata pooled; no infant groups reported."
},
{
"nct": "NCT04605159",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
},
{
"vaccine_groups": [
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "inert",
"offspring": true,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": true,
"patients": false,
"note": "Unadjuvanted RSV maternal vaccine; mothers one comparison, their infants a second. Placebo lyophilized sucrose in NaCl."
},
{
"nct": "NCT04606069",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Regadenoson to treat COVID-19."
},
{
"nct": "NCT04607408",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG003",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG004",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"hiv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "CH505TF gp120 with GLA-SE vs saline in HIV-exposed uninfected newborns; placebo groups were reported pooled. Infants counted as healthy (exposed, not infected)."
},
{
"nct": "NCT04614948",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001",
"EG004"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Took the double-blind groups, including the non-FAS post-dose-1 groups (randomized participants vaccinated against COVID-19 outside the study beforehand); left out the combined all-participants group."
},
{
"nct": "NCT04626297",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Tests lebrikizumab's effect on vaccine responses; both arms get the same vaccines."
},
{
"nct": "NCT04634513",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG006",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG007",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001",
"EG003",
"EG005",
"EG008"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"shigella_etec"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Live attenuated S. flexneri 2a strain that also expresses ETEC antigens (a bacterial live vector); all cohorts pooled. Placebo sodium bicarbonate buffer."
},
{
"nct": "NCT04635423",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"hpv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Took the base-study groups; left out the open-label extension groups. 9vHPV holds aluminium hydroxyphosphate sulfate; placebo 0.9% NaCl."
},
{
"nct": "NCT04642638",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"dna"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"dna"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"dna"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG002",
"EG003",
"EG005"
],
"placebo_content": "inert",
"offspring": false,
"background": "intradermal electroporation (CELLECTRA 2000)"
}
],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "INO-4800 with electroporation, Phase 2 and Phase 3 groups pooled; placebo saline sodium citrate buffer with the same electroporation."
},
{
"nct": "NCT04644484",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [
"rabies"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "SYN023 monoclonal antibodies vs HRIG for post-exposure prophylaxis; both arms get rabies vaccine."
},
{
"nct": "NCT04645966",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"meningococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "MenABCWY compared with Trumenba or Bexsero plus Nimenrix; no placebo-only group."
},
{
"nct": "NCT04649151",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"mrna"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Took the Part 1A blinded groups; left out Part 1B crossover, boosters, Part 2 and Part 3 open-label groups."
},
{
"nct": "NCT04650399",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"chikungunya"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "VLA1553 vs PBS in adolescents."
},
{
"nct": "NCT04652102",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"mrna"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Phase 2b and 3 blinded groups as reported; participants censored at unblinding. Placebo composition not given."
},
{
"nct": "NCT04661579",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"malaria"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "RTS,S/AS01E controlled by rabies vaccine, an active control."
},
{
"nct": "NCT04668339",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"mrna"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Self-amplifying RNA ARCT-021. Took the first randomization's groups A-D (Day 1-207); left out the booster re-randomization groups (E1-H1) and the reactogenicity duplicates (EG008-EG015). Placebo saline."
},
{
"nct": "NCT04673149",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG004",
"platforms": [
"dna"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Placebo only in the Phase IIa part, so took Group 2b vs Group 2a; left out Phase I dose-escalation groups 1a-1c, which had no placebo."
},
{
"nct": "NCT04674189",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"mrna"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "CVnCoV two lots pooled vs placebo in health care workers; placebo composition not given."
},
{
"nct": "NCT04677660",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"mrna"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "TAK-919 is Takeda's mRNA-1273 (platform from the product, not the record); placebo composition not given."
},
{
"nct": "NCT04684914",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [
"hepatitis_b"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "HepTcell is a therapeutic vaccine for chronic hepatitis B."
},
{
"nct": "NCT04707391",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"meningococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "MenABCWY compared with MenACWY then MenB, an active control."
},
{
"nct": "NCT04712110",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "TAK-019 is Takeda's NVX-CoV2373 with Matrix-M (platform and adjuvant from the product, not the record); placebo composition not given."
},
{
"nct": "NCT04722003",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"other"
],
"off_target": true,
"pregnant": false,
"patients": false,
"note": "4CMenB (recombinant proteins + OMV, aluminium hydroxide) given to study protection against gonorrhoea (off-target; 'other' target = gonorrhoea); placebo saline."
},
{
"nct": "NCT04743011",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Nebulized heparin to treat COVID-19."
},
{
"nct": "NCT04754594",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG005",
"platforms": [
"mrna"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001",
"EG006"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
},
{
"vaccine_groups": [
{
"id": "EG003",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG008",
"platforms": [
"mrna"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG004",
"EG009"
],
"placebo_content": "not_stated",
"offspring": true,
"background": "none"
}
],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": true,
"patients": false,
"note": "Maternal blinded groups (HIV-negative and HIV-positive pooled) one comparison, their infants a second; left out the 'placebo then BNT162b2' unblinded groups. Placebo composition not given."
},
{
"nct": "NCT04761822",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Every arm gets mRNA vaccine; placebo arms get one saline dose before the vaccine series, and their groups cover the whole study."
},
{
"nct": "NCT04766086",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"polysaccharide"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "inert",
"offspring": false,
"background": "Tdap"
}
],
"targets": [
"group_b_strep"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "GBS6 + Tdap vs placebo + Tdap. Left out GBS6 + placebo (EG001), which has no placebo-alone group. GBS6 is a CPS-CRM197 conjugate; adjuvant not stated. Placebo saline."
},
{
"nct": "NCT04773665",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG003",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG002",
"EG004"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Two eVLP vaccines (VBI-2902a, VBI-2905a, aluminium phosphate) in Phase 1a and 1b, pooled with both placebo groups; placebo 0.9% NaCl."
},
{
"nct": "NCT04785612",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Same participants reported in three periods; took vaccination-until-challenge (EG000, EG001), the only period before the RSV challenge both arms got, though Day 28-155 is longer. RSVpreF is unadjuvanted; placebo composition not given."
},
{
"nct": "NCT04785794",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001",
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "licensed inactivated influenza vaccine at least 28 days later"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "M2SR is a single-replication (M2-deficient) intranasal live influenza virus, coded live_attenuated; both age cohorts pooled though their IIV differed by age. Placebo saline."
},
{
"nct": "NCT04789577",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"inactivated"
],
"adjuvant": "other"
},
{
"id": "EG001",
"platforms": [
"inactivated"
],
"adjuvant": "other"
},
{
"id": "EG002",
"platforms": [
"inactivated"
],
"adjuvant": "other"
},
{
"id": "EG003",
"platforms": [
"inactivated"
],
"adjuvant": "other"
},
{
"id": "EG004",
"platforms": [
"inactivated"
],
"adjuvant": "other"
},
{
"id": "EG005",
"platforms": [
"inactivated"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG006"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "H7N9 split-virion (Q-Pan) formulations with AS03A or AS03B pooled; placebo composition not given."
},
{
"nct": "NCT04796896",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG006",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG008",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG010",
"platforms": [
"mrna"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG005",
"EG007",
"EG009"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Took Part 2 randomized groups, three age cohorts pooled; left out Part 1 and Part 3 open-label groups, crossover groups and boosters."
},
{
"nct": "NCT04798027",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"mrna"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG002",
"EG006"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Cohort 1 and 2 groups pooled; left out medium dose (EG005), given only in the sentinel cohort, which had no placebo. EG003/EG004 include sentinel participants, as the record pooled them. Placebo 0.9% saline."
},
{
"nct": "NCT04801420",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "unknown"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"lyme"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Took per-arm groups EG000-EG002 (placebo arm got placebo in the booster phase too); left out EG003 (any VLA15, overlaps) and EG004 (all participants). VLA15 adjuvant not stated in the record (investigational)."
},
{
"nct": "NCT04816643",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG012",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG016",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG020",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG023",
"platforms": [
"mrna"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG013",
"EG017",
"EG021",
"EG024"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Took the Phase 2/3 blinded D1-D2 groups of all three age cohorts and the 5-<12 troponin cohort (pooled), which count every randomized participant once. Left out: Phase 1 open-label groups (no placebo); blinded D3 groups (same participants again, and 5-<12 D3 and EG040 have no matching placebo); 12-<16 troponin groups (no placebo); open-label groups (placebo recipients crossed over). Placebo is 0.9% saline."
},
{
"nct": "NCT04817332",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Brensocatib, a DPP1 inhibitor, for severe COVID-19; no vaccine."
},
{
"nct": "NCT04826094",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"dna",
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG001",
"platforms": [
"dna",
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG002",
"platforms": [
"dna",
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG003",
"platforms": [
"dna",
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG004",
"platforms": [
"dna",
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG005",
"platforms": [
"dna",
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG006",
"platforms": [
"dna",
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG007"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"hiv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "All seven vaccine groups got Env-C DNA and gp145 protein with Rehydragel (aluminium hydroxide); some also ALF43 or dmLT. Pooled placebo arm got saline."
},
{
"nct": "NCT04830800",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"other"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"other"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"other"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"other"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG004"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "COVIVAC platform not stated in the record (platform other); EG003 adds CpG1018, the other doses are without adjuvant."
},
{
"nct": "NCT04867174",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Behavioral messaging trial on COVID-19 vaccine take-up; no vaccine randomized."
},
{
"nct": "NCT04869982",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"zoster"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Shingrix (RZV), AS01B adjuvant."
},
{
"nct": "NCT04875533",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"pneumococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "20vPnC/saline vs 13vPnC/PPSV23, an active control."
},
{
"nct": "NCT04886154",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein",
"polysaccharide"
],
"adjuvant": "unknown"
},
{
"id": "EG002",
"platforms": [
"protein",
"polysaccharide"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG001",
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"meningococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Only Phase I (safety lead-in) has placebo arms; Phase II groups all get MenABCWY or the active Bexsero+Menveo control and are left out. MenABCWY-2Gen (MenB proteins plus ACWY conjugates) adjuvant not stated."
},
{
"nct": "NCT04886596",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Tables report the RSVPreF3 arm only as its two re-randomized subgroups (placebo or vaccine annually); together EG001+EG002 are the first-randomized vaccine arm, each participant once. Arexvy, AS01E adjuvant."
},
{
"nct": "NCT04887948",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"polysaccharide"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "inert",
"offspring": false,
"background": "BNT162b2 COVID-19 booster"
}
],
"targets": [
"pneumococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "20vPnC+BNT162b2 vs saline+BNT162b2. EG001 (20vPnC+saline) left out: it could only be a placebo for BNT162b2 against EG000, which is already used. 20vPnC holds aluminium phosphate."
},
{
"nct": "NCT04899336",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"polysaccharide"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"e_coli"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "ExPEC9V O-antigen conjugate, adjuvant not stated. Enrolled for a history of UTI in the past 2 years (patients true)."
},
{
"nct": "NCT04904549",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG001",
"EG003"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Stage 1 (monovalent) and Stage 2 (bivalent) pooled, same design; crossover (EG004) and booster (EG005) groups left out. AS03 adjuvant."
},
{
"nct": "NCT04904744",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Outreach messaging trial; no vaccine randomized."
},
{
"nct": "NCT04908683",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector",
"protein"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Ad26.RSV.preF mixed with RSV preF protein; whether the protein is adjuvanted is not stated."
},
{
"nct": "NCT04917861",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"mrna"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"zika"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Took main-study groups (Day 1-196, covering vaccination); extension-period groups EG004-EG007 are the same participants later and left out."
},
{
"nct": "NCT04940130",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "artemether-lumefantrine before vaccination"
}
],
"targets": [
"malaria"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "PfSPZ: radiation-attenuated, metabolically active but non-replicating whole sporozoites; coded live_attenuated. EG002 (enrolled, no arm) left out."
},
{
"nct": "NCT04951336",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Mushroom supplement tested for its effect on COVID-19 vaccination."
},
{
"nct": "NCT04955626",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"mrna"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001",
"EG004"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Booster in people previously vaccinated with BNT162b2. Substudies A and B pooled (BNT162b2 30 mcg vs saline). Left out EG002 (placebo recipients after crossover) and substudies C-F (no placebo). EG000 includes the vaccine arm's open-label follow-up."
},
{
"nct": "NCT04956575",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"mrna"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Phase 1/2 groups only; Phase 2 NH and extension groups have an Afluria active comparator and no placebo."
},
{
"nct": "NCT04960397",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG006",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001",
"EG003",
"EG005",
"EG007"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Four age/dose cohorts pooled. M2SR is single-replication (no progeny) but the record calls it live attenuated."
},
{
"nct": "NCT04969250",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Immediate vs deferred, one vs two doses; no placebo."
},
{
"nct": "NCT04973449",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "AZD1222 and AZD2816 in every arm; no placebo."
},
{
"nct": "NCT04977479",
"eligible": false,
"exclusion_reason": "groups_not_randomized_arms",
"comparisons": [],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Crossover with 24-hour washout: every participant got vaccine and placebo; the vaccine and placebo groups (3-hour windows) are by injection received, not first-period randomized arms."
},
{
"nct": "NCT04978454",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Influenza challenge virus vs sham inoculum; no vaccine."
},
{
"nct": "NCT04980391",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
},
{
"vaccine_groups": [
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "not_stated",
"offspring": true,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": true,
"patients": true,
"note": "Mothers and infants as two comparisons. Unadjuvanted RSV MAT. High-risk pregnancies (patients true)."
},
{
"nct": "NCT04995081",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Mesenchymal stem cells for Parkinson's disease."
},
{
"nct": "NCT05007080",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Every group gets Ad26.COV2.S; dose levels and one vs two doses."
},
{
"nct": "NCT05012943",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"mrna"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Self-amplifying RNA. Took Day 1-92 groups of Phases 1-3b, before the Day 92 switchover; left out the Day 92-end groups (EG002 mixes arms) and Phase 3c (AstraZeneca active control)."
},
{
"nct": "NCT05027932",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"inactivated"
],
"adjuvant": "unknown"
},
{
"id": "EG001",
"platforms": [
"inactivated"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "IM and IN routes pooled; each vaccine group got saline by the other route as the placebo group did. BPL-1357 adjuvant not stated."
},
{
"nct": "NCT05028361",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"covid19",
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Simultaneous vs sequential COVID-19 mRNA and IIV4; both arms get both."
},
{
"nct": "NCT05045144",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG003",
"platforms": [
"protein"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG004"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "Flu D-QIV influenza vaccine"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "RSV+Flu vs Flu+placebo. Lot groups EG000-EG002 (RSV alone) have no placebo-alone group and are left out. RSV MAT adjuvant not stated in this record. Non-pregnant women."
},
{
"nct": "NCT05062759",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Tezepelumab tested for its effect on an influenza vaccine every arm receives."
},
{
"nct": "NCT05065619",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "CoVLP (plant VLP) with AS03; the low-dose arm has no AE group."
},
{
"nct": "NCT05067933",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "AE tables report only vaccine groups; the Part 2 placebo arm has no AE group."
},
{
"nct": "NCT05069649",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Ergoferon (oral drug) during SARS-CoV-2 vaccination."
},
{
"nct": "NCT05070546",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector",
"protein"
],
"adjuvant": "unknown"
},
{
"id": "EG002",
"platforms": [
"viral_vector",
"protein"
],
"adjuvant": "unknown"
},
{
"id": "EG004",
"platforms": [
"viral_vector",
"protein"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG001",
"EG003",
"EG005"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Three cohorts pooled (healthy 18-59, high-risk 18-59, 65+); patients true for the high-risk cohort. Protein adjuvant not stated."
},
{
"nct": "NCT05071313",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector",
"protein"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "Fluzone High-Dose quadrivalent influenza vaccine"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Took Day 1 groups (before the control group got RSV vaccine on Day 29); Day 29 groups EG002-EG003 are the same participants and left out."
},
{
"nct": "NCT05072080",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"chikungunya"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Three lots pooled; VLP on aluminium hydroxide; placebo is formulation buffer."
},
{
"nct": "NCT05073003",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"other"
],
"adjuvant": "unknown"
},
{
"id": "EG001",
"platforms": [
"other"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"shigella_etec"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Stage 1 adults only; Stage 2 controls are active vaccines (Menveo, Boostrix, Typhim Vi, Infanrix hexa). altSonflex1-2-3 platform not stated (dosed by O-antigen; GMMA-type), adjuvant not stated."
},
{
"nct": "NCT05074303",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Beta-glucan supplement tested for its effect on an influenza vaccine every arm receives."
},
{
"nct": "NCT05074433",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Monoclonal antibodies (casirivimab+imdevimab) as pre-exposure prophylaxis."
},
{
"nct": "NCT05089630",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "unknown"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "unknown"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "unknown"
},
{
"id": "EG003",
"platforms": [
"protein"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG004"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"cmv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Pentamer/gB vaccine described as adjuvanted, adjuvant not named."
},
{
"nct": "NCT05091307",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Placebo arms got Ad26.COV2.S on Day 29 and the AE groups cover Day 1 to end of study, so every group got the vaccine; no first-period groups."
},
{
"nct": "NCT05092646",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Amniotic fluid injection for ankle osteoarthritis."
},
{
"nct": "NCT05096208",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"protein"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Three lots taken; pooled-lots group EG004 duplicates them and is left out. Abrysvo is unadjuvanted."
},
{
"nct": "NCT05099965",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [
"cmv"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Triplex given to adults who already have CMV (and HIV); treats an existing infection."
},
{
"nct": "NCT05116241",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "Boostrix Tdap"
}
],
"targets": [
"tetanus_diphtheria_pertussis"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "BPZE1+Boostrix vs IN placebo+Boostrix. EG000 (BPZE1+IM placebo) has no matching placebo group; post-challenge substudy groups EG003-EG005 are subsets and left out."
},
{
"nct": "NCT05127434",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"mrna"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Part A (first randomization) taken; Part B revaccination groups EG002-EG003 left out."
},
{
"nct": "NCT05135273",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"malaria"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Control is rabies vaccine (Verorab), an active control."
},
{
"nct": "NCT05154578",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG003",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG004"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
},
{
"vaccine_groups": [
{
"id": "EG005",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG006",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG007",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG008",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG009"
],
"placebo_content": "inert",
"offspring": true,
"background": "none"
}
],
"targets": [
"group_b_strep"
],
"off_target": false,
"pregnant": true,
"patients": false,
"note": "Mothers and infants as two comparisons; four schedules pooled."
},
{
"nct": "NCT05158140",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"pneumococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Concomitant vs nonconcomitant with mRNA-1273; every group gets V110 or V114 within the AE period."
},
{
"nct": "NCT05172544",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"inactivated"
],
"adjuvant": "unknown"
},
{
"id": "EG001",
"platforms": [
"inactivated"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"yellow_fever"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "HydroVax-002 adjuvant not stated."
},
{
"nct": "NCT05181657",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Behavioral COVID-19 education intervention."
},
{
"nct": "NCT05182125",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"viral_vector",
"protein"
],
"adjuvant": "other"
},
{
"id": "EG004",
"platforms": [
"viral_vector",
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG002",
"EG005"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"hiv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Parts A and B pooled, same background; Part B groups add CH505TF gp120 with GLA-SE."
},
{
"nct": "NCT05212168",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "norovirus GI.1 challenge inoculum about 29 days after vaccination"
}
],
"targets": [
"norovirus"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Oral replication-defective Ad5 vector expressing norovirus VP1 with a dsRNA adjuvant vs matching placebo tablets; both arms then challenged with Norwalk virus. Groups are by vaccination actually received."
},
{
"nct": "NCT05212948",
"eligible": false,
"exclusion_reason": "groups_not_randomized_arms",
"comparisons": [],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Planned crossover; AE groups span Day 1-435 and pool both periods, so no first-period groups are reported."
},
{
"nct": "NCT05216510",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "SARS-CoV-2 peptide antigens given intradermally as a delayed-type hypersensitivity skin test (diagnostic), with Candin and diluent as within-subject controls; single-group, non-randomized cohorts by infection/vaccination history. Target listed is the disease the test concerns."
},
{
"nct": "NCT05219253",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"zoster"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Shingrix (HZ/su), AS01B; placebo is lyophilised sucrose with saline."
},
{
"nct": "NCT05238025",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Groups as treated (a few misrandomized and multiple enrollers included). MVA carrying RSV antigens; placebo Tris-buffered saline."
},
{
"nct": "NCT05281094",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"norovirus"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "HIL-214 norovirus VLP vaccine; adjuvant not stated."
},
{
"nct": "NCT05289037",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "All arms get COVID-19 vaccines; no placebo."
},
{
"nct": "NCT05301322",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "seasonal inactivated influenza vaccine"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Took Vaccination 1 groups (RSVpreF+SIIV vs placebo+SIIV); Vaccination 2 groups EG001, EG003 are the same participants after crossover. Abrysvo is unadjuvanted."
},
{
"nct": "NCT05310084",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"mrna"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "inert",
"offspring": false,
"background": "seasonal inactivated influenza vaccine"
}
],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Planned crossover: took the Visit 1 groups (BNT162b2+SIIV vs saline+SIIV). Visit 2 groups (EG001, EG003) left out: after the crossover."
},
{
"nct": "NCT05327816",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector",
"protein"
],
"adjuvant": "unknown"
},
{
"id": "EG001",
"platforms": [
"viral_vector",
"protein"
],
"adjuvant": "unknown"
},
{
"id": "EG003",
"platforms": [
"protein"
],
"adjuvant": "unknown"
},
{
"id": "EG004",
"platforms": [
"viral_vector",
"protein"
],
"adjuvant": "unknown"
},
{
"id": "EG005",
"platforms": [
"viral_vector",
"protein"
],
"adjuvant": "unknown"
},
{
"id": "EG006",
"platforms": [
"viral_vector",
"protein"
],
"adjuvant": "unknown"
},
{
"id": "EG007",
"platforms": [
"viral_vector",
"protein"
],
"adjuvant": "unknown"
},
{
"id": "EG008",
"platforms": [
"viral_vector",
"protein"
],
"adjuvant": "unknown"
},
{
"id": "EG009",
"platforms": [
"viral_vector",
"protein"
],
"adjuvant": "unknown"
},
{
"id": "EG010",
"platforms": [
"viral_vector",
"protein"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "AE tables report Cohort 1 only. Ad26 RSV preF vectors plus RSV preF protein; whether the protein is adjuvanted is not stated, so adjuvant unknown."
},
{
"nct": "NCT05330975",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"mrna"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "inert",
"offspring": false,
"background": "Afluria Quadrivalent influenza vaccine"
},
{
"vaccine_groups": [
{
"id": "EG004",
"platforms": [
"mrna"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG005"
],
"placebo_content": "inert",
"offspring": false,
"background": "mRNA-1273.214 COVID-19 vaccine; placebo at day 29 in both"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Part A: mRNA-1345+Afluria vs Afluria+placebo. Part B: mRNA-1345+mRNA-1273.214 vs mRNA-1273.214+placebo. Left out EG000 and EG003 (mRNA-1345+placebo, no placebo-only counterpart) and EG006 (open-label Part C revaccination)."
},
{
"nct": "NCT05349617",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"chikungunya"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "VLP vaccine on aluminium hydroxide; placebo is formulation buffer."
},
{
"nct": "NCT05370040",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "AE groups are Phase 1 saRNA dose cohorts only; the Phase 2 control arm was an EUA/licensed COVID-19 vaccine (active control), not reported in AE groups."
},
{
"nct": "NCT05375838",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG002",
"platforms": [
"mrna"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "inert",
"offspring": false,
"background": "mRNA-1273 COVID-19 vaccine"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "No placebo-only group. mRNA-1010+mRNA-1273 (EG002) vs mRNA-1273+saline (EG000) differs only in mRNA-1010. EG002 could instead pair with EG001 (mRNA-1010+placebo) as an mRNA-1273 comparison; chose the investigational mRNA-1010. mRNA-1073 groups (EG003-EG005) and EG001 left out: no matching placebo group."
},
{
"nct": "NCT05393037",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"pneumococcal"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "V116 then placebo vs PCV15 then PPSV23: active control."
},
{
"nct": "NCT05397119",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG003",
"platforms": [
"protein"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG004"
],
"placebo_content": "inert",
"offspring": false,
"background": "H5N1 inactivated influenza vaccine IM boost at month 6 in all arms"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Intranasal rH5 with nanoemulsion adjuvant (other) and rH5 without adjuvant (EG003, a vaccine group despite its placebo-comparator arm type) vs intranasal saline. Groups span the whole study including the common H5N1 IIV boost."
},
{
"nct": "NCT05422326",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Every group gets aH5N6c; Group 2 gets placebo only as its second dose. No placebo group."
},
{
"nct": "NCT05461131",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "B. pertussis challenge and azithromycin"
}
],
"targets": [
"tetanus_diphtheria_pertussis"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Intranasal live attenuated pertussis vaccine BPZE1 vs placebo, both followed by challenge and azithromycin. Target is pertussis."
},
{
"nct": "NCT05480800",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"polysaccharide"
],
"adjuvant": "unknown"
},
{
"id": "EG001",
"platforms": [
"other",
"polysaccharide"
],
"adjuvant": "unknown"
},
{
"id": "EG002",
"platforms": [
"polysaccharide"
],
"adjuvant": "unknown"
},
{
"id": "EG003",
"platforms": [
"other",
"polysaccharide"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG004"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"typhoid",
"other"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Stage 1 (Europe) only: iNTS-TCV conjugate, and iNTS-GMMA (outer membrane vesicles, platform other) plus TCV, vs placebo+saline. Stage 2 groups left out: control was MenACWY/Tdap/Vi (active). Other target: invasive nontyphoidal Salmonella. Adjuvant not stated."
},
{
"nct": "NCT05489770",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Black elderberry supplement in people with COVID-19; no vaccine."
},
{
"nct": "NCT05500417",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"other"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "All groups get CJCV2 (Campylobacter jejuni conjugate), with or without ALFQ; no placebo. Other target: Campylobacter."
},
{
"nct": "NCT05507450",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"dengue"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "V181 (rDENVdelta30, live attenuated) three potencies vs placebo."
},
{
"nct": "NCT05512949",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"smallpox_mpox"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Open-label MVA-BN dose-sparing comparison; no placebo."
},
{
"nct": "NCT05526716",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"pneumococcal"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Concomitant vs sequential V116 with QIV: both groups get V116 and QIV within the AE period, and the groups are not split at the day-30 crossover, so the placebo-controlled first period is not reported separately."
},
{
"nct": "NCT05559905",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Molnupiravir vs placebo in an RSV challenge model; no vaccine."
},
{
"nct": "NCT05581641",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"mrna"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"malaria"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "BNT165b1 RNA malaria vaccine, three doses, vs matched placebo."
},
{
"nct": "NCT05584202",
"eligible": false,
"exclusion_reason": "groups_not_randomized_arms",
"comparisons": [],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "AE tables report only the two open-label Part 1 dose groups; no Part 2 randomized placebo group appears among the AE groups."
},
{
"nct": "NCT05590403",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG001",
"EG003"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Pooled healthy and at-increased-risk 50-59 strata. EG004 (adults 60+, RSVPreF3 OA only) left out: no placebo group of its own. RSVPreF3 OA (Arexvy) is AS01E-adjuvanted. patients true because one randomized stratum was enrolled for chronic conditions raising RSV risk."
},
{
"nct": "NCT05592223",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [
"tuberculosis"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Open-label BCG challenge model: every arm gets BCG; the arms test isoniazid or rifampin against no drug. No placebo."
},
{
"nct": "NCT05604209",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [
"hiv"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Therapeutic HIV vaccines (ChAdOx1/MVA) in people with HIV on ART."
},
{
"nct": "NCT05604521",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"malaria"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "PfSPZ (radiation-attenuated whole sporozoites, non-replicating; coded live_attenuated as a weakened whole organism against itself, could be other) vs normal saline. Study terminated early; AEs to 28 days after dose 2, before the planned CHMI."
},
{
"nct": "NCT05626803",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"norovirus"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Oral VXA bivalent norovirus tablets (adenovirus-vectored platform, from general knowledge; record gives IU/dose only). EG002 left out: open-label sentinels, not randomized."
},
{
"nct": "NCT05630859",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"other"
],
"adjuvant": "unknown"
},
{
"id": "EG001",
"platforms": [
"other"
],
"adjuvant": "unknown"
},
{
"id": "EG002",
"platforms": [
"other"
],
"adjuvant": "unknown"
},
{
"id": "EG004",
"platforms": [
"other"
],
"adjuvant": "unknown"
},
{
"id": "EG005",
"platforms": [
"other"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG003",
"EG006"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"other"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Pooled Phase 1 and Phase 2 groups. NgG is a GMMA (outer membrane vesicle) vaccine, platform other; adjuvant not stated. Other target: gonorrhoea."
},
{
"nct": "NCT05634811",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG004",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG005"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"lyme"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Took the Overall groups (EG004, EG005); the age-band groups EG000-EG003 are the same participants. VLA15 (OspA) aluminium hydroxide adjuvant from general knowledge, not stated in record. Includes the month-18 booster or placebo."
},
{
"nct": "NCT05639894",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"other"
],
"adjuvant": "unknown"
},
{
"id": "EG001",
"platforms": [
"other"
],
"adjuvant": "unknown"
},
{
"id": "EG002",
"platforms": [
"other"
],
"adjuvant": "unknown"
},
{
"id": "EG003",
"platforms": [
"other"
],
"adjuvant": "unknown"
},
{
"id": "EG004",
"platforms": [
"other"
],
"adjuvant": "unknown"
},
{
"id": "EG005",
"platforms": [
"other"
],
"adjuvant": "unknown"
},
{
"id": "EG007",
"platforms": [
"other"
],
"adjuvant": "unknown"
},
{
"id": "EG008",
"platforms": [
"other"
],
"adjuvant": "unknown"
},
{
"id": "EG009",
"platforms": [
"other"
],
"adjuvant": "unknown"
},
{
"id": "EG010",
"platforms": [
"other"
],
"adjuvant": "unknown"
},
{
"id": "EG011",
"platforms": [
"other"
],
"adjuvant": "unknown"
},
{
"id": "EG012",
"platforms": [
"other"
],
"adjuvant": "unknown"
},
{
"id": "EG018",
"platforms": [
"other"
],
"adjuvant": "unknown"
},
{
"id": "EG019",
"platforms": [
"other"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG006",
"EG013",
"EG020"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Pooled Stage 1 sentinel and main cohorts (18-50) and Stage 2 (60+) primary-vaccination groups. Booster cohort groups EG014-EG017 left out: later re-randomization of Main Cohort participants already counted. Platform other: an LNP-encapsulated candidate whose nucleic acid or antigen the record doesn't name (probably mRNA)."
},
{
"nct": "NCT05654441",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"inactivated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Flulaval (split inactivated, unadjuvanted) vs saline, used as a low-grade inflammatory challenge in a social-behavior study; AEs over about 30 hours."
},
{
"nct": "NCT05687279",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Intranasal live attenuated RSVt vs placebo in infants. The record describes the placebo's form as a suspension of virus, apparently copied from the vaccine; composition treated as not stated. Placebo recipients were contacts of vaccinees in a transmissibility design."
},
{
"nct": "NCT05696080",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"pneumococcal"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "V116 then placebo vs PCV15 then PPSV23: active control."
},
{
"nct": "NCT05762393",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"other"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "rSm-p80 with GLA-SE adjuvant vs saline. Other target: schistosomiasis."
},
{
"nct": "NCT05770895",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [
"hepatitis_b"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Therapeutic HBV arenavirus-vector vaccines (healthy volunteers in Phase 1a, chronic hepatitis B in Phase 1b)."
},
{
"nct": "NCT05782179",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG003",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG004",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG002",
"EG005"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"group_b_strep"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Pooled healthy older and obese/diabetic older cohorts. patients true because one cohort was enrolled for obesity or diabetes."
},
{
"nct": "NCT05788237",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"rsv",
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "SSA: combination RSVpreF+qIRV then placebo vs qIRV then RSVpreF; no placebo in place of RSVpreF at Visit 1, and the Visit 2 placebo group had already got RSVpreF. SSB compares two formulations."
},
{
"nct": "NCT05818124",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Molnupiravir and oseltamivir in an influenza challenge model; no vaccine."
},
{
"nct": "NCT05836012",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "routine infant vaccines"
}
],
"targets": [
"norovirus"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "HIL-214 is the bivalent GI.1/GII.4 norovirus VLP vaccine (as NCT06007781's record says); its aluminium hydroxide (with MPL) adjuvant is from general knowledge, not stated here."
},
{
"nct": "NCT05842967",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Substudy A (18-59, high risk) RSVpreF vs placebo (lyophile matched to RSVpreF, composition not given). Substudy B groups (EG002, EG003) left out: open-label single arm. RSVpreF (Abrysvo) is unadjuvanted."
},
{
"nct": "NCT05886777",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein",
"mrna"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG004"
],
"placebo_content": "inert",
"offspring": false,
"background": "licensed quadrivalent influenza vaccine"
},
{
"vaccine_groups": [
{
"id": "EG006",
"platforms": [
"other"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG005"
],
"placebo_content": "inert",
"offspring": false,
"background": "RSVpreF and bivalent BNT162b2 coadministered"
}
],
"targets": [
"rsv",
"covid19",
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "1: combination RSVpreF+BNT162b2 with QIV (G1) vs QIV+saline (G5). 2: RSVpreF+BNT162b2+QIV (G7) vs RSVpreF+BNT162b2+saline (G6), a QIV comparison; QIV type not named, so platform other and adjuvant unknown. G1 could instead pair with G2 as a QIV comparison. Left out G2, G3, G4 (no matching placebo group)."
},
{
"nct": "NCT05891236",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "MAM01 is a monoclonal antibody against malaria, with CHMI; no vaccine."
},
{
"nct": "NCT05899816",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Rocatinlimab vs placebo for its effect on vaccine antibody responses in atopic dermatitis; the vaccines are not arms of the trial."
},
{
"nct": "NCT05901636",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
},
{
"id": "EG004",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG005",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG006"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Influenza G1 mHA with and without Al(OH)3, one or two doses, vs pooled placebo."
},
{
"nct": "NCT05903183",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"rsv",
"other"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Took the main trial part groups; the observational extension groups (EG003, EG004) are a subset of the same participants. IVX-A12 is an RSV/hMPV VLP vaccine, with MF59 in EG001; placebo is diluent. Other target: human metapneumovirus."
},
{
"nct": "NCT05940194",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "COVIVAC vs AZD1222: active control."
},
{
"nct": "NCT05972993",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG006",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG007",
"platforms": [
"mrna"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001",
"EG003",
"EG005",
"EG008"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Pooled Part A and Part B mRNA-CR-04 doses vs their placebo groups."
},
{
"nct": "NCT05975099",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG005",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG006",
"platforms": [
"mrna"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG007"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"lyme"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "mRNA-1975 and mRNA-1982 dose levels vs vaccine-matching placebo."
},
{
"nct": "NCT06007781",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "aluminium"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"norovirus"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "HIL-214 norovirus GI.1/GII.4 VLP vs placebo; aluminium hydroxide (with MPL) adjuvant from general knowledge, not stated in record."
},
{
"nct": "NCT06022224",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Took the overall groups EG000, EG001; EG002-EG015 repeat the same participants by AE category."
},
{
"nct": "NCT06057064",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "AZD3152 is a monoclonal antibody for COVID-19 pre-exposure prophylaxis."
},
{
"nct": "NCT06060067",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001",
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"dengue"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "TAK-003 vs saline, pooled adult and child cohorts."
},
{
"nct": "NCT06060457",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Coadministered vs sequential mRNA-1345 with Fluzone HD: both groups get mRNA-1345 and Fluzone HD within the AE period, and the groups are not split at the day-22 crossover."
},
{
"nct": "NCT06069544",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG005",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG006",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG007",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG008",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG009",
"platforms": [
"mrna"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG010",
"EG011"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"malaria"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "BNT165c/BNT165d RNA vaccines, pooled across doses and both schedules, vs saline. Title mentions CHMI, not described in the arms."
},
{
"nct": "NCT06097273",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"covid19",
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "mRNA-1083 plus placebo vs licensed influenza plus COVID-19 vaccines: active control."
},
{
"nct": "NCT06097299",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"mrna"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"mrna"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG000"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Took Part A Cohort 1 (2 to <5 years). Cohort 2 groups (EG004-EG006) left out: no placebo. Part B groups (EG007-EG010) left out: re-enrolled subset of Cohort 1, already counted."
},
{
"nct": "NCT06134804",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"polysaccharide"
],
"adjuvant": "unknown"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "high-dose quadrivalent influenza vaccine"
}
],
"targets": [
"e_coli"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Planned crossover: took the post-dose 1 groups (ExPEC9V+HD-QIV vs placebo+HD-QIV). Post-dose 2 groups left out. ExPEC9V is an O-antigen conjugate; adjuvant not stated."
},
{
"nct": "NCT06178991",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"covid19",
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Combination vaccines plus placebo vs licensed COVID-19 plus influenza vaccines, and Cohort 3 vs single vaccines: active controls only."
},
{
"nct": "NCT06237049",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"mrna"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "licensed recombinant influenza vaccine (RIV)"
}
],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "BNT162b2+RIV (G2) vs RIV+saline (G4). G2 could instead pair with G3 (BNT162b2+saline) as an RIV comparison. Left out G1 (combination+saline: no group with saline in place of the combination) and G3."
},
{
"nct": "NCT06279871",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Every group gets ARCT-2303 and an influenza vaccine, coadministered or 28 days apart, and the groups span both doses, so the placebo-controlled first period is not reported separately."
},
{
"nct": "NCT06325657",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
},
{
"vaccine_groups": [
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG003"
],
"placebo_content": "not_stated",
"offspring": true,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": true,
"patients": true,
"note": "Pregnant women living with HIV, and their infants as the offspring comparison. RSVpreF (Abrysvo) unadjuvanted; placebo is matched with no composition given."
},
{
"nct": "NCT06461026",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [
"malaria"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "L9LS is a monoclonal antibody vs saline; every infant later gets R21/Matrix-M, reported as one group (EG006)."
},
{
"nct": "NCT06546423",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated",
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"live_attenuated",
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"other"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Intranasal live attenuated B/HPIV3 vectors carrying HMPV F (listed as both platforms: a live HPIV3 vaccine and a vector for HMPV) vs Lactated Ringer's, the vaccine's diluent. Other targets: human metapneumovirus and parainfluenza 3."
},
{
"nct": "NCT06551181",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG001",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Took the China cohort only (vaccine EG001 vs saline placebo EG002). Left out EG000, the overseas cohort, which got vaccine with no placebo arm of its own and a different follow-up. RSVPreF3 OA is adjuvanted with AS01E."
},
{
"nct": "NCT06593587",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "RSVpreF 120 mcg (prefusion F subunit, unadjuvanted) vs placebo of unstated composition."
},
{
"nct": "NCT06602531",
"eligible": false,
"exclusion_reason": "no_placebo_group",
"comparisons": [],
"targets": [
"influenza"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Control groups (EG003, EG007) got a licensed influenza vaccine at dose 1 and saline only at dose 2, so they are active controls for the self-amplifying mRNA pandemic influenza vaccine; no group got placebo in place of every vaccine dose."
},
{
"nct": "NCT06614725",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"protein"
],
"adjuvant": "other"
},
{
"id": "EG002",
"platforms": [
"protein"
],
"adjuvant": "other"
}
],
"placebo_groups": [
"EG001",
"EG003"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": true,
"note": "Pooled the two age cohorts (>=60 years, and 50-59 at increased risk of RSV-LRTD) into one comparison; placebo is saline. patients true because the 50-59 cohort was enrolled for conditions raising RSV risk; the >=60 cohort is general population. RSVPreF3 OA is adjuvanted with AS01E."
},
{
"nct": "NCT06634797",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"mrna"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "inert",
"offspring": false,
"background": "none"
}
],
"targets": [
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Planned crossover: took the first-period groups (Day 1 injection: mRNA-1273.712 EG000 vs sodium chloride placebo EG002). Left out EG001 and EG003, the Day 29 groups after crossover."
},
{
"nct": "NCT06683352",
"eligible": false,
"exclusion_reason": "vaccine_in_every_arm",
"comparisons": [],
"targets": [
"influenza",
"covid19"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Every group got a COVID-19 vaccine, an investigational influenza vaccine, or both (or licensed influenza plus COVID-19 vaccines); the saline is a second blinding injection, never given in place of all vaccine. The trial compares vaccines and doses."
},
{
"nct": "NCT06705140",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG002",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG003",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"live_attenuated"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG001",
"EG005"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
}
],
"targets": [
"rsv"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Intranasal RSVt (live-attenuated RSV) at low, standard and high doses; pooled cohort 1 (born preterm) and cohort 2 (full-term) into one comparison. Tables report only SD and placebo for cohort 1 (its HD and second control arms have no groups). Preterm-born toddlers aged 6-21 months, listed as healthy volunteers, so patients false."
},
{
"nct": "NCT06831812",
"eligible": false,
"exclusion_reason": "not_a_preventive_vaccine",
"comparisons": [],
"targets": [],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "AV-1959R is a beta-amyloid vaccine against Alzheimer's disease, a non-infectious target; its placebo is adjuvant alone."
},
{
"nct": "NCT07254728",
"eligible": true,
"exclusion_reason": null,
"comparisons": [
{
"vaccine_groups": [
{
"id": "EG000",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG001",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG002"
],
"placebo_content": "not_stated",
"offspring": false,
"background": "none"
},
{
"vaccine_groups": [
{
"id": "EG003",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
},
{
"id": "EG004",
"platforms": [
"viral_vector"
],
"adjuvant": "none"
}
],
"placebo_groups": [
"EG005"
],
"placebo_content": "not_stated",
"offspring": true,
"background": "none"
}
],
"targets": [
"norovirus"
],
"off_target": false,
"pregnant": false,
"patients": false,
"note": "Oral tablet bivalent norovirus vaccine dosed in infectious units (Vaxart's oral adenovirus-vectored platform), so viral_vector; no adjuvant stated, so none by the platform rule, though this platform's vector is reported to express a dsRNA adjuvant. Mothers were lactating, not pregnant; their breast-fed infants (no direct intervention) are taken as an offspring comparison by analogy with the pregnancy rule."
}
]